Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

COVID-19 Updates: COVID-19 Resources » Vaccine Update » Updated Visitor Policy » What We're Doing to Keep You Safe »

View All Information for Patients & Visitors »

View the changes to our visitor policy »

View information for Guest Services »

New to MyHealth?

Manage Your Care From Anywhere.

Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.

Ranjana Advani

Medical oncologist, Lymphoma specialist

Saul A. Rosenberg, MD, Professor of Lymphoma

Bio: Ranjana H. Advani, MD is the Saul Rosenberg Professor of Lymphoma and serves as the Physician Leader of the Lymphoma Clinical Care Program. She specializes in research and treatment of Hodgkin and non-Hodgkin lymphomas and has developed a broad collaborative investigative program, encompassing clinical trials and translational correlates. She is the Principle Investigator on numerous clinical trials. She currently serves on the National Comprehensive Cancer Network (NCCN) non Hodgkin and Hodgkin Lymphoma (vice chair) guidelines panel, Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG) and the National Cancer Institute Lymphoma Steering Committee.

Read Full Bio

Summary
Clinical Trials
Reviews

4.9 out of 5

137 Patient Ratings
97 Patient Comments

Lymphoma Program

875 Blake Wilbur Drive
Palo Alto , CA 94304
Phone: 650-498-6000

More Clinic Information »

Cancer Immunotherapy Program

875 Blake Wilbur Drive
Palo Alto , CA 94304
Phone: 650-498-6000

More Clinic Information »

Summary
Clinical Trials
Reviews

Practice Areas

Professional Education

Fellowship: Stanford University Hematology and Oncology Fellowship (1996) CA
Residency: Stanford University Internal Medicine Residency (1990) CA
Internship: Santa Clara Valley Medical Center Internal Medicine Residency (1987) CA
Board Certification: American Board of Internal Medicine, Medical Oncology (1995)
Medical Education: Bombay University (1982) India

View All

Administrative Appointments

Lymphoma DMG leader, Stanford Cancer Institute (2010 - Present)

View All

Publications

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221–29.
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies
Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., … Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187–94.
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., … Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078–86.
Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy Advani, R., Rosenberg, S. A., & Horning, S. J. (2004). Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. JOURNAL OF CLINICAL ONCOLOGY, 22(8), 1454–59.
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968–73.
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J. T., … Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467–77.
Management of advanced stage Hodgkin lymphoma. Advani, R., Ai, W. Z., & Horning, S. J. (2006). Management of advanced stage Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 4(3), 241–47.
Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., Dick, S., … Kim, Y. H. (2006). Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. ARCHIVES OF DERMATOLOGY, 142(5), 577–84.
Treatment of mantle cell lymphoma: Current approach and future directions Brody, J., & Advani, R. (2006). Treatment of mantle cell lymphoma: Current approach and future directions. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 58(3), 257–65.
Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine Advani, R., Horwitz, S., Zelenetz, A., & Horning, S. J. (2007). Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. LEUKEMIA & LYMPHOMA, 48(3), 521–25.
Non-Hodgkin lymphoma of the breast Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., & Horning, S. (2007). Non-Hodgkin lymphoma of the breast. CANCER, 110(1), 25–30.
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., … Horning, S. J. (2007). Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. JOURNAL OF CLINICAL ONCOLOGY, 25(25), 3902–7.
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Chen, A. I., & Advani, R. H. (2008). Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Journal of the National Comprehensive Cancer Network , 6(4), 428–35.
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., … Lossos, I. S. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. BLOOD, 111(12), 5509–14.
Hodgkin disease/lymphoma. Hoppe, R. T., Advani, R. H., Ambinder, R. F., Bierman, P. J., Bloomfield, C. D., Blum, K., … Zelenetz, A. D. (2008). Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network , 6(6), 594–622.
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953–57.
Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Alizadeh, A. A., & Advani, R. H. (2008). Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clinical Advances in Hematology & Oncology : H&O, 6(12), 899–909.
Targeting CD40 in Waldenstrom's Macroglobulinemia Lee, M., & Advani, R. (2009). Targeting CD40 in Waldenstrom's Macroglobulinemia. CLINICAL LYMPHOMA & MYELOMA, 9(1), 87–89.
Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., … Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667–74.
The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma Maeda, L. S., & Advani, R. H. (2009). The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. CURRENT OPINION IN ONCOLOGY, 21(5), 397–400.
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., … Drachman, J. G. (2009). Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 27(26), 4371–77.
Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Horning, S. J., Juweid, M. E., Schoeder, H., Wiseman, G., McMillan, A., Swinnen, L. J., … Quon, A. (2010). Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. BLOOD, 115(4), 775–77.
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP) Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., … Natkunam, Y. (2010). Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). BRITISH JOURNAL OF HAEMATOLOGY, 148(2), 235–44.
Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment Kohrt, H., & Advani, R. (2009). Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. LEUKEMIA & LYMPHOMA, 50(11), 1773–84.
Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease Kohrt, H., Johannsen, A., Hoppe, R., Horning, S. J., Rosenberg, S. A., Advani, R., & Lee, P. P. (2009). Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease. ONCOLOGY RESEARCH, 18(5-6), 287–92.
Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., Wakelee, H. A., … Adelman, D. C. (2010). Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. CLINICAL CANCER RESEARCH, 16(7), 2167–75.
Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., Losa, R., … Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971–77.
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., … Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324–32.
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI) Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. A., Fisher, R. I., … Horning, S. J. (2010). Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). BRITISH JOURNAL OF HAEMATOLOGY, 151(2), 143–51.
Risk stratification in extranodal natural killer/T-cell lymphoma Kohrt, H., Lee, M., & Advani, R. (2010). Risk stratification in extranodal natural killer/T-cell lymphoma. EXPERT REVIEW OF ANTICANCER THERAPY, 10(9), 1395–1405.
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2011). STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(5), 1374–79.
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma Burington, B., Yue, P., Shi, X., Advani, R., Lau, J. T., Tan, J., … Dornan, D. (2011). CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 3(74).
Current concepts and controversies in the management of early stage Hodgkin lymphoma Maeda, L. S., Lee, M., & Advani, R. H. (2011). Current concepts and controversies in the management of early stage Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 52(6), 962–71.
MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP Alencar, A. J., Malumbres, R., Kozloski, G. A., Advani, R., Talreja, N., Chinichian, S., … Lossos, I. S. (2011). MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. CLINICAL CANCER RESEARCH, 17(12), 4125–35.
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., … Levy, R. (2011). Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. BLOOD, 118(5), 1350–58.
Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus Thuong-Thuong Nguyen, T. T., Gubens, M., Arber, D. A., Advani, R., Juretzka, M., & Aziz, N. (2011). Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus. OBSTETRICS AND GYNECOLOGY, 118(2), 486–89.
Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., … Ganjoo, K. (2012). Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. LEUKEMIA & LYMPHOMA, 53(4), 718–20.
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., … Levy, R. (2012). In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. BLOOD, 119(2), 355–63.
Optimal therapy of advanced Hodgkin lymphoma. Advani, R. (2011). Optimal therapy of advanced Hodgkin lymphoma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2011, 310–16.
Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Hoppe, R. T., … Tran, P. T. (2012). Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease. RADIATION ONCOLOGY, 7.
Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines Powell, A. A., Talasaz, A. A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., … Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. (2012). Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2190–96.
Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499 Smith, M. R., Li, H., Gordon, L., Gascoyne, R. D., Paietta, E., Forero-Torres, A., … Horning, S. J. (2012). Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. JOURNAL OF CLINICAL ONCOLOGY, 30(25), 3119–26.
Cancer Vaccines and T Cell Therapy Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97–S101.
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., … Fowler, N. H. (2013). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. JOURNAL OF CLINICAL ONCOLOGY, 31(1), 88–94.
Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial Advani, R. H., Hoppe, R. T., Baer, D., Mason, J., Warnke, R., Allen, J., … Horning, S. J. (2013). Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. ANNALS OF ONCOLOGY, 24(4), 1044–48.
Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma Scott, D. W., Chan, F. C., Hong, F., Rogic, S., Tan, K. L., Meissner, B., … Gascoyne, R. D. (2013). Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 31(6), 692–700.
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., … Horning, S. J. (2013). Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). JOURNAL OF CLINICAL ONCOLOGY, 31(6), 684–91.
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., & Advani, R. H. (2013). Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY, 31(5), 592–98.
A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. (2005). Investigational New Drugs, In Press.
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). (1999). Blood, 93.
A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies Horwitz, S. M., Vose, J. M., Advani, R., Sankhala, K., Padmanabhan, S., Hamlin, P. A., … O'Connor, O. A. (2008). A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies. BLOOD, 112(11), 557–57.
PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., … Humerickhouse, R. (2010). PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES. Presented at the 15th Annual Meeting of the European-Hematology-Association, BARCELONA,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN: FERRATA STORTI FOUNDATION.
Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies Kahl, B., Roberts, A. W., Seymour, J. F., Advani, R. H., Persky, D. O., Yang, J., … Humerickhouse, R. (2010). Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies. BLOOD, 116(21), 1608–.
Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009 Kwong, Y.-L., Anderson, B. O., Advani, R., Kim, W.-S., Levine, A. M., & Lim, S.-T. (2009). Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. LANCET ONCOLOGY, 10(11), 1093–1101.
Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., … Levy, R. (2010). Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. BLOOD, 116(21), 836–37.
Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003 Tan, D., Rosenberg, S. A., Lavori, P., Sigal, B. M., Levy, R., Hoppe, R. T., … Horning, S. J. (2008). Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for F-18 FDG PET/CT Surveillance? Lagaru, A., Maeda, L. S., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., Gambhir, S. S., & Advani, R. H. (2010). Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for F-18 FDG PET/CT Surveillance? Presented at the 23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), VIENNA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA: SPRINGER.
OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS YARBER, J. L., Otis, S. A., Robinson, B. K., Gordon, L. I., Winter, J. N., Advani, R. H., & Evens, A. M. (2011). OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis Evens, A. M., Advani, R., Lossos, I. S., Press, O. W., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2011). Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. BLOOD, 118(21), 45–46.
Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia Treon, S. P., Tripsas, C. K., Ioakimidis, L., Warren, D., Patterson, C., Heffner, L., … Ghobrial, I. M. (2011). Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. BLOOD, 118(21), 1273–74.
A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Furman, R. R., Eradat, H., DiRienzo, C. G., Hayman, S. R., Hofmeister, C. C., Avignon, N. A., … Lin, T. S. (2011). A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. BLOOD, 118(21), 1581–81.
ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II Das, P., Ng, A., Constine, L. S., Advani, R., Flowers, C., Friedberg, J., … Yunes, M. J. (2011). ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 8(5), 302–8.
Survival in follicular lymphoma: The Stanford experience, 1960-2003. Tan, D., Rosenberg, S. A., Levy, R., Lavori, P., Tibshirani, R., Hoppe, R. T., … Horning, S. J. (2007). Survival in follicular lymphoma: The Stanford experience, 1960-2003. BLOOD, 110(11), 1005A–1005A.
Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003 Tan, D., Rosenberg, S. A., Lavori, P., Levy, R., Hoppe, R., Warnke, R., … Horning, S. J. (2008). Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676] Brody, J. D., Ai, W. Z., Czerwinski, D. K., Advani, R., Horning, S. J., Hoppe, R. T., & Levy, R. (2008). Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676]. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., … Natkunam, Y. (2009). CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA,MA,MA,MA,MA,MA,MA,MA: NATURE PUBLISHING GROUP.
LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., … Natkunam, Y. (2008). LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. BLOOD, 112(11), 1291–91.
Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Talreja, N., … Levy, R. (2009). Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. BLOOD, 114(22), 258–58.
Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP) Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Horning, S. J., … Natkunam, Y. (2009). Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). JOURNAL OF CLINICAL ONCOLOGY, 27(15).
Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., … Levy, R. (2010). Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. BLOOD, 116(21), 1291–92.
In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J., Czerwinski, D., Xing, L., … Levy, R. (2010). In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study. BLOOD, 116(21), 130–30.
IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS Brody, J., Advani, R., Czerwinski, D., Negrin, R., & Levy, R. (2011). IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., … Levy, R. (2011). Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. BLOOD, 118(21), 1323–23.
Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909 Brody, J., Ai, W. Z., Czerwinski, D., Advani, R., Horning, S. J., Ganjoo, K. N., & Levy, R. (2008). Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses Czerwinski, D. K., Brody, J., Kohrt, H. E., Hoppe, R. T., Advani, R. H., & Levy, R. (2012). in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses. BLOOD, 120(21).
The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E., Advani, R., & Horning, S. J. (2009). The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. BLOOD, 114(22), 663–63.
PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499 Smith, M. R., Li, H., Gordon, L., Gascoyne, R., Paietta, E., Forero-Torres, A., … Horning, S. (2011). PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Advani, R. H., Hong, F., Li, H., Kahl, B. S., Pfreundschuh, M., & Ziepert, M. (2011). Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). BLOOD, 118(21), 681–81.
Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years Advani, R. H., Li, H., Hoppe, R. T., Bartlett, N. L., Bennett, J. M., Neuberg, D. S., … Horning, S. J. (2012). Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. BLOOD, 120(21).
Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Yang, D. T., Paietta, E., … Horning, S. J. (2012). Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma. BLOOD, 120(21).
Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). Smith, M. R., Chen, H., Gordon, L., Foran, J., Kahl, B., Advani, R., … Horning, S. J. (2006). Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). JOURNAL OF CLINICAL ONCOLOGY, 24(18), 422S–422S.
Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499 Smith, M. R., Zhang, L., Gordon, L. I., Foran, J., Kahl, B., Gascoyne, R. D., … Horning, S. J. (2007). Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499. BLOOD, 110(11), 121A–121A.
Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial Foss, F., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M., … Acosta, M. (2007). Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial. BLOOD, 110(11), 1011A–1011A.
Non-Hodgkin's Lymphomas Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(3), 288–334.
A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML) Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347–47.
NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., … Yahalom, J. (2011). NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(9), 1020–58.
Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). Kahl, B. S., Advani, R., Kay, N., Lossos, I. S., Evens, A., Gordon, L., … Phan, S. C. (2005). Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). BLOOD, 106(11), 269B–270B.
Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression Krathen, M., Sundram, U., Bashey, S., Sutherland, K., Salva, K., Wood, G. S., … Kim, Y. H. (2012). Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. BLOOD, 120(21).
Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. Molina, A. M., Advani, R., Reddy, S., Hoppe, R., Friedberg, J. W., Sadan, S., … Horwitz, S. M. (2005). Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. BLOOD, 106(11), 934A–934A.
Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome Woo, D., Jones, C., Vanoli-Storz, M., Kohler, S., Reddy, S., Advani, R., … Kim, Y. (2007). Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome. BLOOD, 110(11), 1045A–1045A.
CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma. Dornan, D., Burington, B., Yue, P., Shi, X., Advani, R., Yu, N., … Ebens, A. J. (2009). CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma. BLOOD, 114(22), 1065–65.
Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience. Advani, R., Maeda, L., Hoppe, R. T., Breslin, S., Rosenberg, S. A., Baer, D., … Horning, S. J. (2005). Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience. BLOOD, 106(11), 548A–548A.
PET status after Stanford V chemotherapy predicts outcome in Hodgkins disease Advani, R., Maeda, L., Lavori, P., Hoppe, R., Breslin, S., Rosenberg, S., & Horning, S. (2005). PET status after Stanford V chemotherapy predicts outcome in Hodgkins disease. Presented at the 9th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial Wang, L., Martin, P., Blum, K. A., Kahl, B. S., Maeda, L. S., Advani, R., … Goy, A. (2011). The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. BLOOD, 118(21), 203–4.
Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. Maeda, L. S., Geiger, J. L., Savage, K. J., Rose, J., Pinter-Brown, L. C., Lunning, M. A., … Advani, R. (2012). Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
Role or FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. Maeda, L. S., Horning, S. J., Iagaru, A. H., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., & Advani, R. H. (2009). Role or FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. BLOOD, 114(22), 626–26.
A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Advani, R., Lebmic, D., Brunvand, M., Chen, A. I., Goy, A., Chang, J. E., … Cheson, B. D. (2012). A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). BLOOD, 120(21).
Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., … Rowe, J. M. (1999). Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). BLOOD, 94(10), 383A–383A.
A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. Pollyea, D. A., Smith, S., Fowler, N., Boyd, T. E., Smith, A. M., Sirisawad, M., … Advani, R. (2009). A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. BLOOD, 114(22), 1430–30.
Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Rosenberg, S. A., … Tran, P. T. (2010). Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S546–S547.
Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma Rubenstein, J. L., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., … Damon, L. E. (2011). Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. BLOOD, 118(21), 438–39.
A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzgerald, A. M., & Sikic, B. (2005). A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 234S–234S.
A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Palanca-Wessels, M. C., Flinn, I. W., Sehn, L. H., Patel, M., Sangha, R., Czuczman, M. S., … Assouline, S. E. (2012). A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). BLOOD, 120(21).
Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels Bashey, S., Krathen, M., Sutherland, K., Sundram, U., Lingala, B., Horwitz, S., … Kim, Y. (2012). Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels. Presented at the 75th Annual Meeting of the Society-for-Investigative-Dermatology, RALEIGH,NC,NC,NC,NC,NC,NC,NC,NC: NATURE PUBLISHING GROUP.
Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 Advani, R., Hong, F., Gordon, L. I., Gascoyne, R. D., Wagner, H., Hoppe, R. T., … Horning, S. J. (2011). Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. BLOOD, 118(21), 696–97.
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., … Bartlett, N. L. (2012). A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. CLINICAL CANCER RESEARCH, 18(1), 248–55.
Hodgkin lymphoma. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., … Yahalom, J. (2011). Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 9(9), 1020–58.
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Hoppe, R. T., Advani, R. H., Bierman, P. J., Bloomfield, C. D., Buadi, F., Djulgegovic, B., … Zelenetz, A. D. (2006). Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 210–230.
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial Tan, K. L., Scott, D. W., Hong, F., Kahl, B. S., Fisher, R. I., Bartlett, N. L., … Gascoyne, R. D. (2012). Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. BLOOD, 120(16), 3280–87.
Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies Forero-Torres, A., Fanale, M., Advani, R., Bartlett, N. L., Rosenblatt, J. D., Kennedy, D. A., & Younes, A. (2012). Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. ONCOLOGIST, 17(8), 1073–80.
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2012). Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(5), 589–97.
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Kanakry, J. A., Li, H., Gellert, L. L., Lemas, M. V., Hsieh, W.-S., Hong, F., … Ambinder, R. F. (2013). Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood, 121(18), 3547–53.
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., … Horning, S. J. (2013). The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. BRITISH JOURNAL OF HAEMATOLOGY, 161(1), 76–86.
Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) Olsen, E. A., Rook, A. H., Zic, J., Kim, Y., Porcu, P., Querfeld, C., … Duvic, M. (2011). Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 64(2), 352–404.
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., … Wilson, W. H. (2013). Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 368(15), 1408–16.
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., … Damon, L. E. (2013). Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. BLOOD, 121(5), 745–51.
A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Fishe, G. A., Kuo, T., Cho, C. D., Halsey, J., Jambalos, C. N., Schwartz, E. J., … Wakelee, H. A. (2004). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 248S–248S.
A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., Lum, B. L., & Sikic, B. I. (2002). A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies. Presented at the 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, FRANKFURT,GERMANY: ELSEVIER SCI LTD.
A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., … Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S–6103S.
The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey, J., & Sikic, B. I. (2002). The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. CLINICAL PHARMACOLOGY & THERAPEUTICS, 71(2), P48–P48.
Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients. Horning, S. J., Hoppe, R. T., Advani, R., Warnke, R., Baer, D., Mason, J., & Rosenberg, S. A. (2004). Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients. BLOOD, 104(11), 92A–92A.
Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study Advani, R., Hymes, K., Pohlman, B., Jacobsen, E., McDonnell, J., Belt, R., … Foss, F. (2007). Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study. BLOOD, 110(11), 1012A–1012A.
Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Forero-Torres, A., Berryman, R. B., Advani, R. H., Bartlett, N. L., Chen, R. W., Fanale, M. A., … Matous, J. (2011). Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). BLOOD, 118(21), 1585–86.
Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas Illidge, T., Bouabdallah, R., Chen, R. W., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., … Advani, R. H. (2011). Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas. BLOOD, 118(21), 1335–36.
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas Fanale, M. A., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Horwitz, S. M. (2012). Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas. BLOOD, 120(21).
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Tan, D., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., … Advani, R. H. (2013). Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood, 122(6), 981–87.
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., … Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & Lymphoma, 55(4), 768–72.
Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2007). Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience. Presented at the 7th International Symposium on Hodgkins Lymphoma, COLOGNE,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY: FERRATA STORTI FOUNDATION.
Attitudes and beliefs towards surviorship issues in Hodgkin's disease (HD). Results of focus group discussions with patients treated at stanford university Advani, R., Rosenberg, S., Talreja, N., Hoppe, R., & Horning, S. (2008). Attitudes and beliefs towards surviorship issues in Hodgkin's disease (HD). Results of focus group discussions with patients treated at stanford university. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy Horning, S. J., Hoppe, R. T., Advani, R. H., Breslin, S., McCormick, E., Allen, J., … Rosenberg, S. A. (2007). A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy. Presented at the 7th International Symposium on Hodgkins Lymphoma, COLOGNE,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY: FERRATA STORTI FOUNDATION.
Stage I/II Hodgkin's disease: Comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2007). Stage I/II Hodgkin's disease: Comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience. BLOOD, 110(11), 685A–685A.
Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. Advani, R. H., Hoppe, R. T., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2009). Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. BLOOD, 114(22), 666–67.
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease Kohrt, H. E., Advani, R., Hoppe, R., Rosenberg, S., Horning, S., & Lee, P. P. (2009). Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2006). Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 426S–426S.
Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. Treon, S., Hunter, Z. R., Matous, J., Badros, A., Joyce, R. M., Mannion, B., … Patterson, C. J. (2005). Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. BLOOD, 106(11), 147A–147A.
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248 Treon, S. P., Hunter, Z. R., Matous, J., Joyce, R. M., Mannion, B., Advani, R., … Badros, A. (2007). Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248. CLINICAL CANCER RESEARCH, 13(11), 3320–25.
ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2013). ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma. ONCOLOGY-NEW YORK, 27(8), 786–94.
Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(3), 257–73.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2013). Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 369(6), 507–16.
Targeted Therapy in Relapsed Classical Hodgkin Lymphoma Dinner, S., & Advani, R. (2013). Targeted Therapy in Relapsed Classical Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(8), 968–76.
Non-Hodgkin's Lymphomas Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., … Zafar, N. (2011). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(5), 484–560.
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study Foss, F. M., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M. R., … Bolejack, V. (2013). A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. LEUKEMIA & LYMPHOMA, 54(7), 1373–79.
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Aalipour, A., & Advani, R. H. (2013). Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. British Journal of Haematology, 163(4), 436–43.
Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines Tan, D., Tan, S. Y., Lim, S. T., Kim, S. J., Kim, W.-S., Advani, R., & Kwong, Y.-L. (2013). Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. LANCET ONCOLOGY, 14(12), E548–E561.
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology , 31(32), 4132–39.
Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(12), 1487–98.
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Zelenetz, A. D., Advani, R. H., Buadi, F., Cabanillas, F., Caligiuri, M. A., Czuczman, M. S., … Yahalom, J. (2006). Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 258–310.
Non-Hodgkin's Lymphomas, version 3.2012. Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, version 3.2012. Journal of the National Comprehensive Cancer Network , 10(12), 1487–1498.
Non-Hodgkin's lymphomas. Zelenetz, A. D., Advani, R. H., Byrd, J. C., Czuczman, M. S., Damon, L. E., Duvic, M., … Yunus, F. (2008). Non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 6(4), 356–421.
Non-Hodgkin's lymphomas, version 1.2013. Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin's lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network , 11(3), 257–272.
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 8(3), 288–334.
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Journal of Clinical Oncology , 32(9), 912–18.
Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Horst, K. C., Hancock, S. L., OGNIBENE, G., Chen, C., Advani, R. H., Rosenberg, S. A., … Hoppe, R. T. (2014). Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Annals of Oncology , 25(4), 848–51.
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., … Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology & Oncology, 7, 24-?
ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Terezakis, S. A., Metzger, M. L., Hodgson, D. C., Schwartz, C. L., Advani, R., Flowers, C. R., … Constine, L. S. (2014). ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Pediatric Blood & Cancer, 61(7), 1305–12.
ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma Ng, A., Constine, L. S., Advani, R., Das, P., Flowers, C., Friedberg, J., … Yunes, M. J. (2010). ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma. CURRENT PROBLEMS IN CANCER, 34(3), 211–227.
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era Hosein, P. J., Maragulia, J. C., Salzberg, M. P., Press, O. W., Habermann, T. M., Vose, J. M., … Lossos, I. S. (2014). A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. BRITISH JOURNAL OF HAEMATOLOGY, 165(3), 358–63.
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Chang, J. E., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E. M., Yang, D. T., … Kahl, B. S. (2014). Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood, 123(11), 1665–73.
Non-Hodgkin's lymphomas, version 2.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's lymphomas, version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–46.
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., … Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & Lymphoma, 55(4), 768–72.
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology , 31(32), 4132–4139.
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., … Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.
ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2013). ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Williston Park, N.Y.), 27(8), 786–794.
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology & Oncology, 7, 44-?
Non-Hodgkin's Lymphomas, Version 4.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network , 12(9), 1282–1303.
Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study. JOURNAL OF CLINICAL ONCOLOGY, 32(28), 3137-?
ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2014). ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 11(11), 1026–33.
Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution. Garfin, P. M., Link, M. P., Donaldson, S. S., Advani, R. H., Luna-Fineman, S., Kharbanda, S., … Agarwal-Hashmi, R. (2015). Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution. Biology of Blood and Marrow Transplantation , 21(2), 326–34.
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Aalipour, A., & Advani, R. H. (2014). Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeutic Advances in Hematology, 5(4), 121–33.
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., … Kahl, B. S. (2015). Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Journal of Clinical Oncology , 33(7), 740–48.
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network , 13(3), 326–362.
Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., … Hoppe, R. T. (2015). Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology, Biology, Physics, 92(1), 99–106.
Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era King, M. T., Donaldson, S. S., Link, M. P., Natkunam, Y., Advani, R. H., & Hoppe, R. T. (2015). Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 92(1), 67–75.
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., … Advani, R. H. (2015). Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia. NEW ENGLAND JOURNAL OF MEDICINE, 372(15), 1430–40.
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., … Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679–87.
Optimal Therapy of Advanced Hodgkin Lymphoma Advani, R. (2011). Optimal Therapy of Advanced Hodgkin Lymphoma. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 310–16.
How I treat nodular lymphocyte predominant Hodgkin lymphoma Advani, R. H., & Hoppe, R. T. (2013). How I treat nodular lymphocyte predominant Hodgkin lymphoma. BLOOD, 122(26), 4182–88.
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Gopal, A. K., Ramchandren, R., O'Connor, O. A., Berryman, R. B., Advani, R. H., Chen, R., … Zain, J. (2012). Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. BLOOD, 120(3), 560–68.
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O'Connor, O. A., … Oki, Y. (2014). Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. BLOOD, 123(20), 3095–3100.
Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? Diefenbach, C., & Advani, R. (2014). Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 28(1), 105-?
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., … Bartlett, N. L. (2015). Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. BLOOD, 125(9), 1394–1402.
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., … Pohlman, B. (2015). A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 168(6), 811–19.
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma Illidge, T., Bouabdallah, R., Chen, R., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., … Advani, R. (2015). Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. LEUKEMIA & LYMPHOMA, 56(3), 703–10.
Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus Dimopoulos, M. A., Kastritis, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., … Treon, S. P. (2014). Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. BLOOD, 124(9), 1404–11.
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies Marostica, E., Sukbuntherng, J., Loury, D., de Jong, J., de Trixhe, X. W., Vermeulen, A., … Poggesi, I. (2015). Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 75(1), 111–21.
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies Han, T. H., Chen, R., Advani, R., Berryman, R. B., Smith, S. E., Forero-Torres, A., … Engert, A. (2013). Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 72(1), 241–49.
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Journal of Clinical Oncology , 32(28), 3137–43.
Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging. Iberri, D. J., Hoppe, R. T., & Advani, R. H. (2015). Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging. Current Treatment Options in Oncology, 16(9), 45-?
Hodgkin Lymphoma, Version 2.2015 Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2015). Hodgkin Lymphoma, Version 2.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(5), 554–86.
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404) Swinnen, L. J., Li, H., Quon, A., Gascoyne, R., Hong, F., Ranheim, E. A., … Advani, R. H. (2015). Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). BRITISH JOURNAL OF HAEMATOLOGY, 170(1), 56–65.
Management of nodular lymphocyte predominant Hodgkin lymphoma Advani, R. H., & Hoppe, R. T. (2015). Management of nodular lymphocyte predominant Hodgkin lymphoma. HEMATOLOGICAL ONCOLOGY, 33, 90–95.
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., … Horning, S. J. (2015). Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Journal of Clinical Oncology , 33(17), 1936–42.
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., … Morschhauser, F. (2015). Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. LANCET ONCOLOGY, 16(6), 704–15.
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., … Lenz, G. (2015). Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. LEUKEMIA, 29(7), 1578–86.
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., … Lenz, G. (2015). Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia, 29(7), 1578–86.
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies Roberts, A. W., Advani, R. H., Kahl, B. S., Persky, D., Sweetenham, J. W., Carney, D. A., … Seymour, J. F. (2015). Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies. BRITISH JOURNAL OF HAEMATOLOGY, 170(5), 669–78.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Rule, S. (2015). Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. BLOOD, 126(6), 739–45.
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402 Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., … Horning, S. J. (2015). A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. BRITISH JOURNAL OF HAEMATOLOGY, 170(5), 679–86.
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., … Staudt, L. M. (2015). Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. NATURE MEDICINE, 21(8), 922–26.
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., … Blum, K. A. (2015). Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. AMERICAN JOURNAL OF HEMATOLOGY, 90(9), 778–83.
Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Journal of Clinical Oncology , 32(9), 912–18.
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., … Horning, S. J. (2015). Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. JOURNAL OF CLINICAL ONCOLOGY, 33(17), 1936–U111.
Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT) Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., … Kahl, B. S. (2015). Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). JOURNAL OF CLINICAL ONCOLOGY, 33(7).
Non-Hodgkin's Lymphomas, Version 2.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–46.
Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging. Iberri, D. J., Hoppe, R. T., & Advani, R. H. (2015). Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging. Current Treatment Options in Oncology, 16(9), 360-?
ACR appropriateness criteria follow-up of Hodgkin lymphoma. Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2014). ACR appropriateness criteria follow-up of Hodgkin lymphoma. Journal of the American College of Radiology , 11(11), 1026–1033 e3.
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., … Blum, K. A. (2015). Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 90(9), 778–83.
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58.
Postibrutinib outcomes in patients with mantle cell lymphoma Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., … Blum, K. A. (2016). Postibrutinib outcomes in patients with mantle cell lymphoma. BLOOD, 127(12), 1559–63.
ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. Dabaja, B. S., Advani, R., Hodgson, D. C., Dhakal, S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2015). ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. American Journal of Clinical Oncology, 38(6), 610–20.
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era Diefenbach, C. S., Li, H., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., … Advani, R. H. (2015). Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. BRITISH JOURNAL OF HAEMATOLOGY, 171(4), 530–38.
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network , 13(3), 326–362.
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58.
Intra-CSF rituximab for lymhomatous meningitis - Reply Rubenstein, J., Abrey, L., Advani, R., Shuman, M., Tsai, T., & O'Brien, J. (2007). Intra-CSF rituximab for lymhomatous meningitis - Reply. JOURNAL OF CLINICAL ONCOLOGY, 25(28), 4509–11.
Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2016). Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(2), 196–231.
Speeding up PET/MR for cancer staging of children and young adults. Aghighi, M., Pisani, L. J., Sun, Z., Klenk, C., Madnawat, H., Fineman, S. L., … Daldrup-Link, H. E. (2016). Speeding up PET/MR for cancer staging of children and young adults. European Radiology, -?
Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Matthews, J. M., Bhatt, S., Patricelli, M. P., Nomanbhoy, T. K., Jiang, X., Natkunam, Y., … Lossos, I. S. (2016). Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood, 128(2), 239–48.
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis Kim, S. J., Yoon, D. H., Jaccard, A., Chng, W. J., Lim, S. T., Hong, H., … Kim, W. S. (2016). A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. LANCET ONCOLOGY, 17(3), 389–400.
A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. LEUKEMIA & LYMPHOMA, 57(3), 604–8.
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Advani, R. H., Ansell, S. M., Lechowicz, M. J., Beaven, A. W., Loberiza, F., Carson, K. R., … M Vose, J. (2016). A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. British Journal of Haematology, 172(4), 535–44.
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Stuart, R., Bartlett, N. L., … Drachman, J. G. (2015). Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia & Lymphoma, 56(9), 2569–78.
Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma. Horst, K. C., Fero, K. E., Hancock, S. L., Advani, R. H., Ikeda, D. M., Daniel, B., … Hoppe, R. T. (2016). Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma. American Journal of Clinical Oncology, 39(2), 114–19.
A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leukemia & Lymphoma, 57(3), 604–8.
Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia Xu, L., Hunter, Z. R., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., … Treon, S. P. (2016). Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia. BRITISH JOURNAL OF HAEMATOLOGY, 172(5), 735–44.
Diffuse Large B-Cell Lymphoma Version 1.2016. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2016). Diffuse Large B-Cell Lymphoma Version 1.2016. Journal of the National Comprehensive Cancer Network , 14(2), 196–231.
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., … Wilson, C. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(11), 1228–30.
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., … Wilson, C. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(11), 1225–27.
Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring Minamimoto, R., Fayad, L., Advani, R., Vose, J., Macapinlac, H., Meza, J., … Quon, A. (2016). Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. RADIOLOGY, 280(1), 220–29.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., … Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. BLOOD, 127(20), 2375–90.
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Castillo, J. J., Palomba, M. L., Advani, R., & Treon, S. P. (2016). Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology, 7(4), 179–86.
2 Gy?×?2 for palliative treatment of mantle cell lymphoma. White, E. C., Advani, R., & Hoppe, R. T. (2016). 2 Gy?×?2 for palliative treatment of mantle cell lymphoma. Leukemia & Lymphoma, 57(9), 2219–21.
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., … Shipp, M. A. (2016). PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology , 34(23), 2690–97.
ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. Roberts, K. B., Younes, A., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., … Constine, L. S. (2016). ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. American Journal of Clinical Oncology, 39(4), 384–95.
Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. (2016). British Journal of Haematology.
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Leblond, V., Kastritis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., … Dimopoulos, M. A. (2016). Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 128(10), 1321–28.
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., … Porcu, P. (2016). NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network , 14(9), 1067–79.
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Varma, G., Johnson, T. P., & Advani, R. H. (2016). Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Clinical Advances in Hematology & Oncology : H&O, 14(7), 543–54.
Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. Lynch, R. C., & Advani, R. H. (2016). Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 35, e376–85.
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. SCIENCE TRANSLATIONAL MEDICINE, 8(364).
Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Roemer, M. G. M., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., … Rodig, S. J. (2016). Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 4(11), 910–16.
Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., … Kahl, B. S. (2016). Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia.
Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., … Porcu, P. (2016). Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(9), 1067–79.
Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia. Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Demos, M., … Treon, S. P. (2017). Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia. Blood.
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., … Cheson, B. D. (2017). Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(5), 1167–76.
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., … Armand, P. (2016). Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. BLOOD, 128(21), 2489–96.
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Bartlett, N. L., Smith, M. R., Siddiqi, T., Advani, R. H., O'Connor, O. A., Sharman, J. P., … Jacobsen, E. D. (2016). Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia & Lymphoma, 1–10.
ACR Appropriateness Criteria (R) Recurrent Hodgkin Lymphoma Winkfield, K. M., Advani, R. H., Ballas, L. K., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2016). ACR Appropriateness Criteria (R) Recurrent Hodgkin Lymphoma. ONCOLOGY-NEW YORK, 30(12), 1099–1108.
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Furman, R. R., Eradat, H. A., DiRienzo, C. G., Hofmeister, C. C., Hayman, S. R., Leonard, J. P., … Lin, T. S. (2017). Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet. Haematology, 4(1), e24–e34.
ACR Appropriateness Criteria (R) Hodgkin Lymphoma-Favorable Prognosis Stage I and II Dhakal, S., Advani, R., Ballas, L. K., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2016). ACR Appropriateness Criteria (R) Hodgkin Lymphoma-Favorable Prognosis Stage I and II. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 39(6), 535–44.
The landscape of new drugs in lymphoma. Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., … Vose, J. (2016). The landscape of new drugs in lymphoma. Nature Reviews. Clinical Oncology.
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Casulo, C., O'Connor, O., Shustov, A., Fanale, M., Friedberg, J. W., Leonard, J. P., … Horwitz, S. (2017). T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute, 109(2).
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., … Foss, F. M. (2016). A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer.
Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Hsi, E. D., Horwitz, S. M., Carson, K. R., Pinter-Brown, L. C., Rosen, S. T., Pro, B., … Foss, F. M. (2017). Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical Lymphoma, Myeloma & Leukemia.
NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2017). NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(3), 293–311.
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2017). NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network , 15(3), 293–311.
A Prospective Cohort Study of Patients With Peripheral T-Cell Lymphoma in the United States Carson, K. R., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., … Foss, F. M. (2017). A Prospective Cohort Study of Patients With Peripheral T-Cell Lymphoma in the United States. CANCER, 123(7), 1174–83.
The landscape of new drugs in lymphoma Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., … Vose, J. (2017). The landscape of new drugs in lymphoma. NATURE REVIEWS CLINICAL ONCOLOGY, 14(6), 335–46.
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry Bartlett, N. L., Smith, M. R., Siddiqi, T., Advani, R. H., O'Connor, O. A., Sharman, J. P., … Jacobsen, E. D. (2017). Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. LEUKEMIA & LYMPHOMA, 58(7), 1607–16.
Hodgkin Lymphoma Version 1.2017 Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2017). Hodgkin Lymphoma Version 1.2017. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(5), 608–38.
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Younes, A., HILDEN, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., … Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology .
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Tao, L., Clarke, C. A., Rosenberg, A. S., Advani, R. H., Jonas, B. A., Flowers, C. R., & Keegan, T. H. M. (2017). Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. British Journal of Haematology.
Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., … Alizadeh, A. A. (2016). Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. BLOOD, 128(22).
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2017). Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 15(5), 608–38.
How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach. Muehe, A. M., Theruvath, A. J., Lai, L., Aghighi, M., Quon, A., Holdsworth, S. J., … Daldrup-Link, H. E. (2017). How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach. Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging.
Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center Porter, J. B. (2017). Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center, 13(8), e673–e682.
Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Lynch, R. C., Gratzinger, D., & Advani, R. H. (2017). Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Current Treatment Options in Oncology, 18(7), 45.
INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT Kim, S. J., Park, Y., Chang, M. H., Oh, S. Y., Kwak, J. Y., Yang, D. H., … Kim, W. S. (2015). INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT. HAEMATOLOGICA, 100, 5.
Analysis of Breast Cancer Subtypes in Women who Develop Breast Cancer following Mantle Irradiation for Hodgkin's Disease Horst, K. C., Hancock, S., Advani, R., Horning, S., Rosenberg, S., & Hoppe, R. T. (2010). Analysis of Breast Cancer Subtypes in Women who Develop Breast Cancer following Mantle Irradiation for Hodgkin's Disease. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S206–S207.
Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management Iberri, D. J., Kwong, B., Stevens, L., Coutre, S. E., Kim, J., Sabile, J., & Advani, R. H. (2015). Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management. BLOOD, 126(23).
Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies. Poggesi, I., Sardu, M. L., Marostica, E., Sukbuntherng, J., Chang, B. Y., de Jong, J., … Wang, M. (2015). Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies. CLINICAL CANCER RESEARCH, 21.
Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study Wang, M., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2014). Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. BLOOD, 124(21).
Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up Wang, M., Rule, S. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2012). Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. BLOOD, 120(21).
Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study Dreyling, M., Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., … Blum, K. A. (2015). Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study. Oncology Research and Treatment, 38, 18–19.
Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy Wang, M., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., … Rule, S. (2014). Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. BLOOD, 124(21).
Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study Rule, S., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., … Wang, M. (2015). Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study. BRITISH JOURNAL OF HAEMATOLOGY, 169, 59.
Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma Stilgenbauer, S., Rule, S., Wang, M. L., Martin, P., Auer, R., Kahl, B. S., … Blum, K. A. (2014). Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma. ONCOLOGY RESEARCH AND TREATMENT, 37, 34–35.
PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME Rule, S., Wang, M. L., Martin, P., Auer, R., Kahl, B. S., Jurczak, W., … Blum, K. A. (2014). PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME. HAEMATOLOGICA, 99, 150.
Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up Wang, M., Rule, S. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2012). Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. BLOOD, 120(21).
IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY Rule, S., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., … Wang, M. (2015). IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY. VALUE IN HEALTH, 18(3), A300–A301.
PRELIMINARY RESULTS OF A PHASE II RANDOMIZED STUDY (ROMULUS) OF POLATUZUMAB VEDOTIN OR PINATUZUMAB VEDOTIN PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL) Morschhauser, F., Flinn, I., Advani, R., Sehn, L., Kolibaba, K., Press, O., … Sharman, J. (2014). PRELIMINARY RESULTS OF A PHASE II RANDOMIZED STUDY (ROMULUS) OF POLATUZUMAB VEDOTIN OR PINATUZUMAB VEDOTIN PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL). HAEMATOLOGICA, 99, 525.
TWO DOSES OF POLATUZUMAB VEDOTIN (POV, ANTI-CD79B ANTI-BODY-DRUG CONJUGATE) PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE LEVEL Sharman, J., Flinn, I., Advani, R., Diefenbach, C., Kolibaba, K., Press, O., … Morschhauser, F. (2015). TWO DOSES OF POLATUZUMAB VEDOTIN (POV, ANTI-CD79B ANTI-BODY-DRUG CONJUGATE) PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE LEVEL. HAEMATOLOGICA, 100, 272.
Phase I trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients Robert, F., Hurwitz, H., Uronis, H., Verschraegen, C., Advani, R., Chen, A., … Evanchik, M. (2008). Phase I trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients. EJC SUPPLEMENTS, 6(12), 91–92.
Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results. Horwitz, S. M., Vose, J. M., Advani, R., Sankhala, K., Padmanabhan, S., Hamlin, P. A., … O'Connor, O. A. (2009). Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results. BLOOD, 114(22), 667–68.
A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients Robert, F., Verschraegen, C., Hurwitz, H., Uronis, H., Advani, R., Chen, A., … Michelson, G. (2009). A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
BIOMARKERS IN RELAPSED/REFRACTORY DLBCL AND FL PATIENTS TREATED WITH POLATUZUMAB VEDOTIN: RESULTS FROM THE PHASE II CLINICAL TRIAL (ROMULUS) Penuel, E., Mundt, K., Bourgon, R., Sumiyoshi, T., Flinn, I., Press, O., … Hirata, J. (2016). BIOMARKERS IN RELAPSED/REFRACTORY DLBCL AND FL PATIENTS TREATED WITH POLATUZUMAB VEDOTIN: RESULTS FROM THE PHASE II CLINICAL TRIAL (ROMULUS). HAEMATOLOGICA, 101, 578.
IBRUTINIB IN PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA IS HIGHLY ACTIVE, PRODUCES DURABLE RESPONSES, AND IS IMPACTED BY MYD88 AND CXCR4 MUTATION STATUS Treon, S., Tripsas, C., Meid, K., Warren, D., Varma, G., Green, R., … Advani, R. (2015). IBRUTINIB IN PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA IS HIGHLY ACTIVE, PRODUCES DURABLE RESPONSES, AND IS IMPACTED BY MYD88 AND CXCR4 MUTATION STATUS. HAEMATOLOGICA, 100, 311.
The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability Xu, L., Hunter, Z., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., … Treon, S. P. (2015). The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. BLOOD, 126(23).
Magnetic Resonance Imaging of Tumor Associated Macrophages: Clinical Translation. Aghighi, M., Theruvath, A. J., Pareek, A., Pisani, L., Alford, R., Muehe, A. M., … Daldrup-Link, H. E. (2018). Magnetic Resonance Imaging of Tumor Associated Macrophages: Clinical Translation. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013) Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(10), 1530.
Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., … Levy, R. (2015). Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. BLOOD, 126(23).
Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL) Scherer, F., Kurtz, D. M., Green, M. R., Newman, A. M., Klass, D. M., Zhou, L., … Alizadeh, A. A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. Kurtz, D. M., Green, M. R., Bratman, S. V., Liu, C.-L., Glover, C., Keane, C., … Alizadeh, A. A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. Khodadoust, M. S., Chu, M. P., Czerwinski, D., McDonald, K., Long, S., Kohrt, H. E., … Levy, R. (2015). Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy. Brownstein, C. M., Adriaens, L., Bannerji, R., Chavez, J. C., Levy, R., Ansell, S. M., … Kohrt, H. E. (2015). First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma Alencar, A. J., Malumbres, R., Advani, R., Talreja, N., Shyam, R., Briones, J., … Lossos, I. S. (2009). MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma. BLOOD, 114(22), 258–59.
A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations Ohgami, R. S., Chen, J. S., Advani, R., Natkunam, Y., & Warnke, R. A. (2014). A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations. LABORATORY INVESTIGATION, 94, 366A–367A.
A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations Ohgami, R. S., Chen, J. S., Advani, R., Natkunam, Y., & Warnke, R. A. (2014). A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations. MODERN PATHOLOGY, 27, 366A–367A.
CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., … Natkunam, Y. (2009). CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas. LABORATORY INVESTIGATION, 89, 275A.
KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas Kunder, C. A., Roncador, G., Advani, R. H., Gualco, G., Bacchi, C. E., Sabile, J. M., … Natkunam, Y. (2017). KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 148(6), 465–76.
Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience Maeda, L. S., Hoppe, R. T., Warnke, R. A., Natkunam, Y., Rosenberg, S. A., Homing, S. J., & Advani, R. (2010). Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., … Shipp, M. A. (2015). PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. BLOOD, 126(23).
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium Stevens, W. B. C., Mendeville, M., Redd, R., Clear, A. J., Bladergroen, R., Calaminici, M., … de Jong, D. (2017). Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. HAEMATOLOGICA, 102(8), 1413–23.
Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., … Bartlett, N. L. (2011). Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. BLOOD, 118(21), 1154.
New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? Spinner, M. A., Advani, R. H., Connors, J. M., Azzi, J., & Diefenbach, C. (2018). New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? American Society of Clinical Oncology Education Book, 38.
Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era. Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., & Hoppe, R. T. (2014). Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., & Hoppe, R. T. (2014). Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S677–S678.
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. (2017). Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. BLOOD, 130(25), 2709–17.
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., … Advani, R. H. (2018). Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. BLOOD, 131(11), 1183–94.
Advances in the Management of Primary Mediastinal Large B-Cell Lymphoma Advani, R. H. (2018). Advances in the Management of Primary Mediastinal Large B-Cell Lymphoma. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 16(1), 33–34.
Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation Lynch, R. C., & Advani, R. H. (2017). Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation. CASE REPORTS IN ONCOLOGY, 10(3), 813–18.
NCCN Guidelines (R) Insights Hodgkin Lymphoma, Version 1.2018 Featured Updates to the NCCN Guidelines Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Armand, P., … Ogba, N. (2018). NCCN Guidelines (R) Insights Hodgkin Lymphoma, Version 1.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(3), 245–54.
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2018). Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. BLOOD, 131(19), 2120–24.
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis Henderson, T. O., Parsons, S. K., Wroblewski, K. E., Chen, L., Hong, F., Smith, S. M., … Evens, A. M. (2018). Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. CANCER, 124(1), 136–44.
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group Constine, L. S., Yahalom, J., Ng, A. K., Hodgson, D. C., Wirth, A., Milgrom, S. A., … Hoppe, R. T. (2018). The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(5), 1100–1118.
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05) Swinnen, L. J., O'Neill, A., Imus, P. H., Gujar, S., Schiff, D., Kleinberg, L. R., … Grossman, S. A. (2018). Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). ONCOTARGET, 9(1), 766–73.
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network Federico, M., Bellei, M., Marcheselli, L., Schwartz, M., Manni, M., Tarantino, V., … Advani, R. H. (2018). Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. BRITISH JOURNAL OF HAEMATOLOGY, 181(6), 760–69.
Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Spinner, M. A., Advani, R. H., Hoppe, R. T., Lowsky, R., & Muffly, L. S. (2018). Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Blood Advances, 2(13), 1547–50.
Bulky Mediastinal Classical Hodgkin Lymphoma in Young Women Percival, M.-E. M., Hoppe, R. T., & Advani, R. H. (2014). Bulky Mediastinal Classical Hodgkin Lymphoma in Young Women. ONCOLOGY-NEW YORK, 28(3), 253-+.
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression Kim, Y. H., Tavallaee, M., Rozati, S., Sundram, U., Salva, K., Wood, G. S., … Horwitz, S. M. (2014). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression. BLOOD, 124(21).
Randomized Phase III Trial Comparing ABVD plus Radiotherapy and the Stanford V.Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A-Subset Analysis of the US Intergroup Trial E2496 Advani, R., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, S., Gascoyne, R. D., … Horning, S. J. (2010). Randomized Phase III Trial Comparing ABVD plus Radiotherapy and the Stanford V.Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A-Subset Analysis of the US Intergroup Trial E2496. BLOOD, 116(21), 185–86.
Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma Kohrt, H. E., Chu, J., Brody, J., Czerwinski, D. K., Chester, C., Sadaram, M., … Levy, R. (2014). Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. BLOOD, 124(21).
A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., … Horning, S. J. (2010). A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496). BLOOD, 116(21), 185.
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs Tefferi, A., Rajkumar, S. V., Gertz, M. A., Kyle, R. A., Kantarjian, H., Allison, J., … Wiernik, P. H. (2015). In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. MAYO CLINIC PROCEEDINGS, 90(8), 996–1000.
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project Bellei, M., Foss, F. M., Shustov, A. R., Horwitz, S. M., Marcheselli, L., Kim, W. S., … Federico, M. (2018). The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. HAEMATOLOGICA, 103(7), 1191–97.
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J., … Advani, R. (2018). Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. BLOOD, 132(1), 40–48.
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making Melani, C., Advani, R., Roschewski, M., Walters, K. M., Chen, C. C., Baratto, L., … Wilson, W. H. (2018). End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. HAEMATOLOGICA, 103(8), 1337–44.
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785246.
Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. Advani, R. H., Hong, F., Ganjoo, K. N., Manola, J. B., Swinnen, L. J., Habermann, T. M., & Horning, S. J. (2009). Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. BLOOD, 114(22), 667.
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Evens, A. M., Advani, R. H., Helenowski, I. B., Fanale, M., Smith, S. M., Jovanovic, B. D., … Hamlin, P. A. (2018). Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018790139.
Novel Approaches in Waldenstrom Macroglobulinemia. Spinner, M. A., Varma, G., & Advani, R. H. (2018). Novel Approaches in Waldenstrom Macroglobulinemia. Hematology/Oncology Clinics of North America, 32(5), 875–90.
Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C. L., … Alizadeh, A. A. (2016). Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. BLOOD, 128(22).
Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., … Alizadeh, A. A. (2016). Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. BLOOD, 128(22).
Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome Kritharis, A., Kanakry, J. A., Sehn, L. H., Feldman, T., Kroll, A., Gascoyne, R. D., … Evens, A. M. (2014). Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. BLOOD, 124(21).
Circulating tumor DNA (ctDNA) in B-cell lymphoma Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating tumor DNA (ctDNA) in B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 182, 16–17.
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia Castillo, J. J., Gustine, J. N., Meid, K., Dubeau, T. E., Xu, L., Yang, G., … Treon, S. P. (2018). Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia. HAEMATOLOGICA, 103(10), E466–E468.
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., … Flinn, I. W. (2018). First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget, 9(16), 13023–35.
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., … Smith, S. M. (2018). CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine, 379(18), 1711–21.
Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. Advani, R., Oki, Y., Shustov, A. R., Grove, L. E., & Bartlett, N. (2012). Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results Jacobsen, E. D., Advani, R. H., Oki, Y., Sharman, J., Horwitz, S. M., Forero-Torres, A., … Bartlett, N. L. (2012). A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results. BLOOD, 120(21).
The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation Weil, C., Qian, Y., Von Eyben, R., Daadi, S. E., Corbelli, K. S., Rosenberg, S. A., … Hoppe, R. T. (2018). The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(3), S189.
Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiation Therapy Moding, E. J., Advani, R. H., Rosenberg, S. A., & Hoppe, R. T. (2018). Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(3), S189–S190.
Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Spinner, M. A., Varma, G., & Advani, R. H. (2018). Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. British Journal of Haematology.
Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Spinner, M. A., & Advani, R. H. (2018). Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology. American Society of Hematology. Education Program, 2018(1), 200–206.
Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. Moding, E. J., Advani, R., Rosenberg, S. A., & Hoppe, R. T. (2018). Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 129(3), 507–12.
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation Kharfan-Dabaja, M. A., Kumar, A., Ayala, E., Hamadani, M., Reimer, P., Gisselbrecht, C., … Savani, B. N. (2017). Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(11), 1826–38.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., … Trumper, L. (2018). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet (London, England).
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Morschhauser, F., Flinn, I., Advani, R. H., Sehn, L. H., Kolibaba, K. S., Press, O. W., … Sharman, J. P. (2014). Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). JOURNAL OF CLINICAL ONCOLOGY, 32(15).
Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R., Connors, J. M., … Straus, D. J. (2019). Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. Jin, M. C., Kurtz, D. M., Esfahani, M. S., Scherer, F., Craig, A. F. M., Soo, J., … Alizadeh, A. A. (2017). Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 35.
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Park, S. I., Horwitz, S. M., Foss, F. M., Pinter-Brown, L. C., Carson, K. R., Rosen, S. T., … Shustov, A. R. (2019). The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer.
CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma. Advani, R., Volkmer, J.-P., & Chao, M. P. (2019). CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine, 380(5), 497–98.
CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma REPLY Advani, R., Volkmer, J.-P., & Chao, M. P. (2019). CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma REPLY. NEW ENGLAND JOURNAL OF MEDICINE, 380(5), 497–98.
Reply to J. Wang et al. Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2019). Reply to J. Wang et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801907.
Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia Castillo, J. J., Gustine, J., Meid, K., Dubeau, T., Keezer, A., Allan, J. N., … Treon, S. P. (2018). Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. BLOOD, 132.
A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicullar Lymphoma (FL) from in E2408 Hong, F., Evens, A. M., Novotny, P. J., Habermann, T. M., Advani, R. H., Gascoyne, R. D., … Thanarajasingam, G. (2018). A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicullar Lymphoma (FL) from in E2408. BLOOD, 132.
Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing Schroers-Martin, J. G., Garofalo, A., Soo, J., Jin, M. C., Kurtz, D. M., Buedts, L., … Alizadeh, A. A. (2018). Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. BLOOD, 132.
Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., … Alizadeh, A. A. (2018). Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. BLOOD, 132.
No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission Lynch, R. C., Sundaram, V., Desai, M., Henry, S., Wood, D., Daadi, S., … Advani, R. (2018). No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission. BLOOD, 132.
Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F) Hong, F., Thanarajasingam, G., Ansell, S. M., Ambinder, R. F., Cohen, J. B., Robertson, M., … Diefenbach, C. (2018). Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). BLOOD, 132.
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy Carreau, N. A., Pail, O., Armand, P., Merryman, R. W., Advani, R. H., Spinner, M. A., … Diefenbach, C. (2018). Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. BLOOD, 132.
The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas Horwitz, S. M., O'Connor, O. A., Pro, B., Illidge, T. M., Fanale, M. A., Advani, R. H., … Truemper, L. (2018). The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas. BLOOD, 132.
A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis Savas, H., Allen, P., Evens, A. M., Pro, B., Dillehay, G., Rademaker, A., … Winter, J. N. (2018). A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis. BLOOD, 132.
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing) Advani, R. H., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., … Herrera, A. F. (2018). Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). BLOOD, 132.
Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers Kothari, S. K., Li, S., Medeiros, L. J., Ayers, E. C., Landsburg, D. J., Bond, D. A., … Torka, P. (2018). Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. BLOOD, 132.
The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid (R) Continuation (BIONIC) Study Baratto, L., Jegede, O., Hong, F., Habermann, T. M., Advani, R., Gascoyne, R. D., … Evens, A. M. (2018). The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid (R) Continuation (BIONIC) Study. BLOOD, 132.
A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I) Diefenbach, C., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M., David, K. A., … Ansell, S. M. (2018). A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). BLOOD, 132.
Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes Bannerji, R., Arnason, J. E., Advani, R., Brown, J. R., Allan, J. N., Ansell, S. M., … Topp, M. S. (2018). Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes. BLOOD, 132.
Enhanced bioavailability of oral paclitaxel by valspodar (PSC 833), an inhibitor of small bowel P-glycoprotein and cytochrome P450. Sikic, B. I., Advani, R., Fisher, G. A., Halsey, J., Cohen, P., & Lum, B. L. (2000). Enhanced bioavailability of oral paclitaxel by valspodar (PSC 833), an inhibitor of small bowel P-glycoprotein and cytochrome P450. CLINICAL CANCER RESEARCH, 6, 4580S.
A phase I trial of doxil, paclitaxel and valspodar (PSC 833). Advani, R., Fisher, G., Lum, B., Halsey, J., & Sikic, B. I. (2000). A phase I trial of doxil, paclitaxel and valspodar (PSC 833). CLINICAL CANCER RESEARCH, 6, 4504S.
SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin lymphoma: Final results of a phase I dose-escalation study Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Harrop, K., … Drachman, J. G. (2008). SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin lymphoma: Final results of a phase I dose-escalation study. ANNALS OF ONCOLOGY, 19, 115.
Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) Horning, S. J., Bartlett, N. L., Breslin, S., Advani, R. H., Hoppe, R. T., Ekstrand, B. C., & Lucas, J. B. (2007). Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). BLOOD, 110(11), 198A.
A phase II study of derdleukin diftitox (Ontak (R)) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: Interim analysis. Foss, F. M., Sjak-Shie, N., Goy, A., Advani, R., Jacobsen, E., & Acosta, M. (2006). A phase II study of derdleukin diftitox (Ontak (R)) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: Interim analysis. BLOOD, 108(11), 696A–697A.
SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Shankles, B., … Drachman, J. G. (2006). SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. BLOOD, 108(11), 209A.
A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study. Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Harrop, K., Drachman, J. G., & Advani, R. (2006). A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 430S.
SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies. Hurwitz, H., Gordon, M., Advani, R., Ebbinghaus, S., Mendelson, D., Wakelee, H., … Adelman, D. (2006). SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 136S.
Phase I trial of SNS-595 in patients (pts) with advanced malignancies. Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., … Adelman, D. (2005). Phase I trial of SNS-595 in patients (pts) with advanced malignancies. CLINICAL CANCER RESEARCH, 11(24), 9056S.
A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma. Advani, R. H., Furman, R. R., Rosenblatt, J. D., Younes, A., Forero-Torres, A., Harrop, K. L., … Drachman, J. G. (2005). A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma. BLOOD, 106(11), 433A.
Marked improvement in staging accuracy in mycosis fungoides/Sezary syndrome using integrated positron emission tomography and computed tomography (PET/CT) Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Dick, S. E., Chow, S., … Kim, Y. H. (2004). Marked improvement in staging accuracy in mycosis fungoides/Sezary syndrome using integrated positron emission tomography and computed tomography (PET/CT). BLOOD, 104(11), 854A–855A.
Phase I trial of SNS-595 in patients with advanced malignancies. Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., … Adelman, D. (2005). Phase I trial of SNS-595 in patients with advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 159S.
A phase 1 trial of weekly SNS-595 in patients (PTS) with refractory cancer Ebbinghaus, S., Gordon, M., Advani, R., Hurwitz, H., Mendelson, D., Wakelee, H., … Adelman, D. (2006). A phase 1 trial of weekly SNS-595 in patients (PTS) with refractory cancer. CANCER RESEARCH, 66(8).
Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. Lynch, R. C., & Advani, R. H. (2016). Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (36), e376–e385.
Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Advani, R. H., Flinn, I., Popplewell, L., Forero-Torres, A., Bartlett, N. L., Ghosh, N., … Smith, S. M. (2018). Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. JOURNAL OF CLINICAL ONCOLOGY, 36(15).
Prognostic value of LUGANO, EORTC, PERCIST and IHP criteria in patients with diffuse large B cell lymphoma based on 18F-FDG PET/CT Wu, F., Baratto, L., Minamimoto, R., Advani, R., Sabile, J., & Mittra, E. (2016). Prognostic value of LUGANO, EORTC, PERCIST and IHP criteria in patients with diffuse large B cell lymphoma based on 18F-FDG PET/CT. JOURNAL OF NUCLEAR MEDICINE, 57.
The role of interim 18F-FDG PET/CT in DLBCL patients: SUV max, SUV mean and SUV peak as predictive metabolic parameters of prognosis Baratto, L., Wu, F., Minamimoto, R., Sabile, J., Advani, R., & Mittra, E. (2016). The role of interim 18F-FDG PET/CT in DLBCL patients: SUV max, SUV mean and SUV peak as predictive metabolic parameters of prognosis. JOURNAL OF NUCLEAR MEDICINE, 57.
Prognostic role of baseline 18F-FDG PET/CT in DLBCL patients Baratto, L., Wu, F., Minamimoto, R., Sabile, J., Advani, R., & Mittra, E. (2016). Prognostic role of baseline 18F-FDG PET/CT in DLBCL patients. JOURNAL OF NUCLEAR MEDICINE, 57.
UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA Rule, S., Wang, M., Martin, P., Auer, R., Kahl, B., Jurczak, W., … Blum, K. (2013). UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA. HAEMATOLOGICA, 98, 489.
Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA. Soo, J., Kurtz, D. M., Scherer, F., Craig, A. F. M., Jin, M. C., Westin, J. R., … Alizadeh, A. A. (2017). Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA. JOURNAL OF CLINICAL ONCOLOGY, 35.
Clinical Impact of the 2016 Update to the WHO Lymphoma Classification (vol 18, 45, 2017) Lynch, R. C., Gratzinger, D., & Advani, R. H. (2017). Clinical Impact of the 2016 Update to the WHO Lymphoma Classification (vol 18, 45, 2017). CURRENT TREATMENT OPTIONS IN ONCOLOGY, 18(10), 60.
Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG) Dabaja, B. S., Zelenetz, A. D., Ng, A. K., Tsang, R. W., Qi, S., Allen, P. K., … Yahalom, J. (2017). Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). ANNALS OF ONCOLOGY, 28(9), 2185–90.
PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA Witzig, T., Sokol, L., Jacobsen, E., Advani, R., Mondejar, R., Piris, M., … Gualberto, A. (2017). PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA. HAEMATOLOGICA, 102, 222.
A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001 Ribrag, V., Chavez, J. C., Kaplan, J. B., Vitolo, U., Chandler, J. C., Santoro, A., … Kuruvilla, J. (2016). A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001. BLOOD, 128(22).
Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial Kanakry, J. A., Hong, F., Martinez-Maza, O., Horning, S. J., Gordon, L. I., Gascoyne, R. D., … Ambinder, R. F. (2016). Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. BLOOD, 128(22).
Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. R. (2016). Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. BLOOD, 128(22).
Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1+Arm 2 Results from a Multicenter, Open-Label Phase 2 Study Fowler, N., Nastoupil, L., de Vos, S., Knapp, M., Flinn, I. W., Chen, R. W., … Palomba, M. L. (2016). Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1+Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. BLOOD, 128(22).
Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-delta,gamma Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab Casulo, C., Sancho, J.-M., Van Eygen, K., de Vos, S., Mercadal, S., Johnson, R. J., … Goy, A. (2016). Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-delta,gamma Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. BLOOD, 128(22).
Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia Treon, S. P., Tsakmaklis, N., Meid, K., Yang, G., Chen, J. G., Liu, X., … Hunter, Z. (2016). Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. BLOOD, 128(22).
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Bannerji, R., Brown, J. R., Advani, R. H., Arnason, J., O'Brien, S. M., Allan, J. N., … Brownstein, C. (2016). Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. BLOOD, 128(22).
Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma Herrera, A. F., Bartlett, N. L., Ramchandren, R., Vose, J. M., Moskowitz, A. J., Feldman, T. A., … Advani, R. H. (2016). Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. BLOOD, 128(22).
Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E) Diefenbach, C. S., Hong, F., David, K. A., Cohen, J., Robertson, M., Advani, R., … Ansell, S. (2016). Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). BLOOD, 128(22).
Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Chen, J., … Treon, S. P. (2016). Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia. BLOOD, 128(22).
BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA LaCasce, A., Bociek, G., Sawas, A., Caimi, P., Agura, E., Matous, J., … Advani, R. (2016). BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. HAEMATOLOGICA, 101, 45–46.
A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412) Diefenbach, C. S. M., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., Fenske, T. S., … Ansell, S. (2016). A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412). HAEMATOLOGICA, 101, 44–45.
OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA TREATED ON US COOPERATIVE GROUP PROTOCOLS: AN ADULT INTERGROUP (E2496) AND CHILDREN'S ONCOLOGY GROUP (COG AHOD0031) COMPARATIVE ANALYSIS Henderson, T. O., Parsons, S. K., Wroblewski, K., Chen, L., Hong, F., Smith, S., … Evens, A. M. (2016). OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA TREATED ON US COOPERATIVE GROUP PROTOCOLS: AN ADULT INTERGROUP (E2496) AND CHILDREN'S ONCOLOGY GROUP (COG AHOD0031) COMPARATIVE ANALYSIS. HAEMATOLOGICA, 101, 34–35.
SEQUENTIAL BRENTUXIMAB VEDOTIN AND ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE FOR OLDER PATIENTS WITH UNTREATED HODGKIN LYMPHOMA: FINDINGS FROM A PHASE II WINDOW STUDY Evens, A. M., Hamlin, P. A., Nabhan, C., Advani, R., Fanale, M., Petrich, A., … Gordon, L. I. (2016). SEQUENTIAL BRENTUXIMAB VEDOTIN AND ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE FOR OLDER PATIENTS WITH UNTREATED HODGKIN LYMPHOMA: FINDINGS FROM A PHASE II WINDOW STUDY. HAEMATOLOGICA, 101, 20.
THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB (PCI-32765), HAS PREFERENTIAL ACTIVITY IN THE ACTIVATED B CELL-LIKE (ABC) SUBTYPE OF RELAPSED/REFRACTORY (R/R) DLBCL: INTERIM PHASE 2 RESULTS deVos, S., Wilson, W., Gerecitano, J., Goy, A., Kenkre, V., Barr, P., … Staudt, L. (2013). THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB (PCI-32765), HAS PREFERENTIAL ACTIVITY IN THE ACTIVATED B CELL-LIKE (ABC) SUBTYPE OF RELAPSED/REFRACTORY (R/R) DLBCL: INTERIM PHASE 2 RESULTS. HAEMATOLOGICA, 98, 490.
A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma Burington, B., Advani, R., Shi, X., Yue, P., Lau, J., Yu, S.-F., … Dornan, D. (2009). A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma. CANCER RESEARCH, 69.
Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia Thomas, S. K., Harb, W. A., Beck, J. T., Nashat, G., Palomba, M. L., Ansell, S. M., … Agrawal, S. (2015). Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. BLOOD, 126(23).
Frontline Treatment of CD30+Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up Horwitz, S. M., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R., Pro, B., … Fanale, M. A. (2015). Frontline Treatment of CD30+Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. BLOOD, 126(23).
Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05] Swinnen, L. J., O'Neill, A., Imus, P. H., Gujar, S., Schiff, D., Kleinberg, L., … Grossman, S. (2015). Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]. BLOOD, 126(23).
Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study Yasenchak, C. A., Halwani, A., Advani, R., Ansell, S., Budde, L. E., Burke, J. M., … Bartlett, N. L. (2015). Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. BLOOD, 126(23).
Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412) Diefenbach, C. S., Hong, F., Cohen, J. B., Robertson, M. J., Ambinder, R. F., Fenske, T. S., … Ansell, S. (2015). Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). BLOOD, 126(23).
Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study Fowler, N., Nastoupil, L., de Vos, S., Knapp, M., Flinn, I. W., Chen, R., … Palomba, M. L. (2015). Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. BLOOD, 126(23).
A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma Moskowitz, C. H., Fanale, M. A., Shah, B. D., Advani, R. H., Chen, R., Kim, S., … Forero-Torres, A. (2015). A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma. BLOOD, 126(23).
Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma LaCasce, A. S., Bociek, G., Sawas, A., Caimi, P. F., Agura, E., Matous, J., … Advani, R. (2015). Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. BLOOD, 126(23).
A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results Sawas, A., Savage, K. J., Perez, R., Advani, R. H., Butturini, A., Lackey, J., … O'Connor, O. A. (2015). A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results. BLOOD, 126(23).
Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma Fowler, N., Boyd, T. E., Sharman, J. P., Smith, S. M., Clow, F., Chu, A. D., & Advani, R. H. (2015). Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. BLOOD, 126(23).
Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y-90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499 Smith, M. R., Li, H., Hong, F., Gordon, L. I., Gascoyne, R. D., Paietta, E., … Kahl, B. S. (2015). Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y-90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. BLOOD, 126(23).
Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis Henderson, T. O., Parsons, S. K., Wroblewski, K., Chen, L., Hong, F., Smith, S. M., … Evens, A. M. (2015). Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis. BLOOD, 126(23).
Treatment of angioimmunoblastic T-cell lymphoma (AILD) with cyclosporine. Advani, R., Horwitz, S., Harandi, A., Lee, M., Noy, A., Zelenetz, A. D., & Horning, S. J. (2003). Treatment of angioimmunoblastic T-cell lymphoma (AILD) with cyclosporine. BLOOD, 102(11), 180A.
Multicenter study for comparison of FLT and FDG PET/CT for early interim therapy monitoring of diffuse large B-cell lymphoma Minamimoto, R., Vose, J., Advani, R., Fayad, L., Macapinlac, H., Meza, J., … Quon, A. (2014). Multicenter study for comparison of FLT and FDG PET/CT for early interim therapy monitoring of diffuse large B-cell lymphoma. JOURNAL OF NUCLEAR MEDICINE, 55.
Prospective multicenter comparison of early interim F-18-FLT PET/CT versus F-18-FDG PET/CT Minamimoto, R., Fayad, L., Advani, R., Vose, J., Macapinlac, H., Meza, J., … Quon, A. (2015). Prospective multicenter comparison of early interim F-18-FLT PET/CT versus F-18-FDG PET/CT. JOURNAL OF NUCLEAR MEDICINE, 56(3).
Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). Forero-Torres, A., Moskowitz, C., Advani, R. H., Shah, B. D., Kostic, A., Albertson, T. M., … Fanale, M. A. (2014). Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). JOURNAL OF CLINICAL ONCOLOGY, 32(15).
A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). Diefenbach, C. S. M., Li, H., Kahl, B. S., Robertson, M. J., Cohen, J., Advani, R. H., … Ansell, S. M. (2015). A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
CD30+expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project Federico, M., Bellei, M., Luminari, S., Horwitz, S. M., Montoto, S., Zucca, E., … Vose, J. (2015). CD30+expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. Advani, R. H., Flinn, I., Sharman, J. P., Diefenbach, C. S. M., Kolibaba, K. S., Press, O. W., … Morschhauser, F. (2015). Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). Bartlett, N. L., Farber, C. M., Yasenchak, C. A., Ansell, S. M., Advani, R. H., Knapp, M. H., … Halwani, A. S. (2015). Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies Marostica, E., Sukbuntherng, J., Loury, D., Jong, J. D., de Trixhie, X. W., Vermeulen, A., … Poggesi, I. (2014). Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies. CANCER RESEARCH, 74(19).
Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy LaCasce, A., Bociek, R. G., Matous, J., Sawas, A., Caimi, P., Ansell, S. M., … Advani, R. (2014). Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy. BLOOD, 124(21).
Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak, C. A., Farber, C. M., Budde, L. E., Ansell, S. M., Advani, R., Holkova, B., … Bartlett, N. L. (2014). Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. BLOOD, 124(21).
Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Morschhauser, F., Flinn, I., Advani, R. H., Diefenbach, C. S., Kolibaba, K., Press, O. W., … Sharman, J. P. (2014). Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. BLOOD, 124(21).
Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. R. (2014). Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. BLOOD, 124(21).
Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL) Pinter-Brown, L., Foss, F. M., Carson, K. R., Horwitz, S. M., Rosen, S. T., Pro, B., … Park, S. I. (2014). Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL). BLOOD, 124(21).
Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma Moskowitz, C. H., Forero-Torres, A., Shah, B. D., Advani, R., Hamlin, P., Kim, S., … Fanale, M. A. (2014). Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. BLOOD, 124(21).
Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study Bartlett, N. L., Smith, M. R., Advani, R., Feldman, T., Savage, K. J., Palanca-Wessels, M. C., & Siddiqi, T. (2014). Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. BLOOD, 124(21).
BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP. ANNALS OF ONCOLOGY, 25.
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Management in the Modern Era King, M., Donaldson, S., Link, M., Advani, R., & Hoppe, R. (2014). Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Management in the Modern Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S67–S68.
Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized US Intergroup Trial E2496 Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N., Connors, J. M., … Horning, S. J. (2011). Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized US Intergroup Trial E2496. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. Brody, J., Advani, R., Weng, W., Czerwinski, D., Alizadeh, A. A., Kohrt, H. E., … Levy, R. (2011). Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma in the First Salvage Setting: Interim Results LaCasce, A., Sawas, A., Bociek, R. G., Ansell, S., Vose, J., O'Meara, M., & Advani, R. (2014). A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma in the First Salvage Setting: Interim Results. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(2), S161.
Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial Foss, F. M., Sjak-Shie, N. N., Goy, A., Advani, R., & Jacobsen, E. D. (2010). Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study Advani, R., Sharman, J. P., Smith, S. M., Pollyea, D. A., Boyd, T. E., Grant, B. W., … Fowler, N. H. (2010). Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
Confirmation of the prognostic value of the EORTC/WHO classification of primary cutaneous B-cell lymphoma in the United States: The Stanford University experience Reddy, S. A., Kim, Y. H., Advani, R. H., & Hoppe, R. T. (2007). Confirmation of the prognostic value of the EORTC/WHO classification of primary cutaneous B-cell lymphoma in the United States: The Stanford University experience. JOURNAL OF CLINICAL ONCOLOGY, 25(18).
Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. R. (2012). Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. BLOOD, 120(21).
Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity Salzberg, M. P., Maragulia, J. C., Press, O. W., Habermann, T. M., Vose, J. M., Bast, M., … Lossos, I. S. (2012). Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. BLOOD, 120(21).
A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402). Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., … Horning, S. J. (2012). A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402). BLOOD, 120(21).
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma Fowler, N. H., Advani, R. H., Sharman, J., Smith, S. M., McGreivy, J., Kunkel, L., … Boyd, T. E. (2012). The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma. BLOOD, 120(21).
Evaluation of Radiation Therapy for NK-T-cell Lymphoma of the Head and Neck Chan, C., Zeidan, Y. H., Advani, R., Le, Q., & Hoppe, R. T. (2012). Evaluation of Radiation Therapy for NK-T-cell Lymphoma of the Head and Neck. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S618–S619.
SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN IN NEWLY DIAGNOSED PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA Fanale, M., Advani, R., Bartlett, N. L., Davies, A., Illidge, T., Kennedy, D. A., & Shustov, A. R. (2012). SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN IN NEWLY DIAGNOSED PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA. ANNALS OF ONCOLOGY, 23, 348.
Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma Advani, R., Pro, B., Kennedy, D., & Fanale, M. (2012). Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 66(4), AB4.
Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update Advani, R. H., Shustov, A. R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Pro, B. (2011). Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. BLOOD, 118(21), 204.
ABBREVIATED 8 WK CHEMOTHERAPY (CT) plus INVOLVED NODE RADIOTHERAPY (INRT) FOR NON-BULKY STAGE I-II HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE STANFORD G5 STUDY Advani, R. H., Horning, S. J., Jonathan, E., Daadi, S., Allen, J., Rosenberg, S. A., & Hoppe, R. T. (2011). ABBREVIATED 8 WK CHEMOTHERAPY (CT) plus INVOLVED NODE RADIOTHERAPY (INRT) FOR NON-BULKY STAGE I-II HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE STANFORD G5 STUDY. ANNALS OF ONCOLOGY, 22, 179.
THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND WELL TOLERATED IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES: FINAL RESULTS FROM A PHASE I STUDY Advani, R. H., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B. W., Kolibaba, K. S., … Fowler, N. H. (2011). THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND WELL TOLERATED IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES: FINAL RESULTS FROM A PHASE I STUDY. ANNALS OF ONCOLOGY, 22, 135.
A PHASE 2B TRIAL COMPARING DACETUZUMAB plus R-ICE VS PLACEBO plus R-ICE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Bartlett, N. L., Stuart, R., … Drachman, J. G. (2011). A PHASE 2B TRIAL COMPARING DACETUZUMAB plus R-ICE VS PLACEBO plus R-ICE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA. ANNALS OF ONCOLOGY, 22, 132.
DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL) Shustov, A., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Pro, B. (2011). DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL). ANNALS OF ONCOLOGY, 22, 125.
EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496 Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N., Connors, J. M., … Horning, S. J. (2011). EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496. ANNALS OF ONCOLOGY, 22, 117–18.
Functional characterization of Rab14 GTPase and its role in membrane trafficking and vesicular transport Junutula, Advani, R. J., Peden, A. A., de Maziere, A., Klumperman, J., & Scheller, R. H. (2002). Functional characterization of Rab14 GTPase and its role in membrane trafficking and vesicular transport. MOLECULAR BIOLOGY OF THE CELL, 13, 227A–228A.
The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies Burger, J. A., O'Brien, S., Fowler, N., Advani, R., Sharman, J. P., Furman, R. R., … Blum, K. A. (2010). The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies. BLOOD, 116(21), 32.
Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-centre case series Gopal, A. K., Ramchandren, R., Berryman, R. B., Advani, R. H., Chen, R., Smith, S., … O'Connor, O. A. (2011). Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-centre case series. BONE MARROW TRANSPLANTATION, 46, S36.
Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Shustov, A. R., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Pro, B. (2010). Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. BLOOD, 116(21), 423–24.
The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study Fowler, N., Sharman, J. P., Smith, S. M., Boyd, T., Grant, B., Kolibaba, K. S., … Advani, R. (2010). The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study. BLOOD, 116(21), 425.
A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY Fowler, N., Sharman, J., Smith, S., Pollyea, D., Boyd, T., Grant, B., … Advani, R. (2010). A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 371.
Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma Pohlman, B., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., … Foss, F. M. (2009). Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma. BLOOD, 114(22), 379.
A prospective trial of involved field radiation (IFRT) plus chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy Horning, S. J., Hoppe, R. T., Advani, R. H., Breslin, S., Allen, J., Hancock, S. L., & Rosenberg, S. A. (2007). A prospective trial of involved field radiation (IFRT) plus chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy. JOURNAL OF CLINICAL ONCOLOGY, 25(18).
A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma. Advani, R., De Vos, S., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Forero-Torres, A. (2008). A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma. BLOOD, 112(11), 368.
Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404 Horning, S. J., Juweid, M. E., Schoder, H., Wiseman, G., McMillan, A., Swinnen, L. J., … Quon, A. (2008). Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404. BLOOD, 112(11), 145.
Schedule and concentration dependent increase of coagulation times and complement split products in phase I/II trials of an antisense oligonucleotide targeted to protein kinase C-alpha(ISIS 3521/ISI641A). Advani, R., Lum, B. L., Fisher, G. A., Grant, P., Halsey, J., Yuen, A., … Sikic, B. I. (1999). Schedule and concentration dependent increase of coagulation times and complement split products in phase I/II trials of an antisense oligonucleotide targeted to protein kinase C-alpha(ISIS 3521/ISI641A). BLOOD, 94(10), 94B.
Phase II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer: Updated survival and time to progression data. Yuen, A., Halsey, J., Fisher, G., Advani, R., Moore, M., Saleh, M., … Sikic, B. (2001). Phase II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer: Updated survival and time to progression data. CLINICAL CANCER RESEARCH, 7(11), 3681S.
A phase I trial of ISIS 3521 (IS1641A), an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with cancer. Yuen, A., Sikic, B. I., Advani, R., Fisher, G., Halsey, J., Lum, B., … Dorr, A. (1999). A phase I trial of ISIS 3521 (IS1641A), an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with cancer. CLINICAL CANCER RESEARCH, 5, 3846S–3847S.
Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). Advani, R., Saba, H. I., Tallman, M., Rowe, J. M., Wiernik, P. H., Ramek, J., … Greenberg, P. (1997). Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). BLOOD, 90(10), 2260.
Phase I/II trial of ISIS3521, an antisense inhibitor of PKC alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Yuen, A., Halsey, J., Lum, B., Fisher, G., Advani, R., Geary, R., … Sikic, B. I. (2000). Phase I/II trial of ISIS3521, an antisense inhibitor of PKC alpha, with carboplatin and paclitaxel in non-small cell lung cancer. CLINICAL CANCER RESEARCH, 6, 4572S.
Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) Advani, R., Saba, H., Rowe, J. M., Tallman, M., Wiernik, P., Ramek, J., … Greenberg, P. (1996). Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). BLOOD, 88(10), 847.
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., … Sharman, J. (2019). Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). The Lancet. Haematology.
New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? Spinner, M. A., Advani, R. H., Connors, J. M., Azzi, J., & Diefenbach, C. (2018). New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 38, 626–36.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Rule, S. (2015). Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood, 126(6), 739–45.
Improving care with portfolio of physician-led cancer quality measures at an academic center Porter, J., Smith, A. S., Winget, M., Rosenthal, E. L., Seshadri, S. B., Vetteth, Y., … Blayney, D. W. (2017). Improving care with portfolio of physician-led cancer quality measures at an academic center. JOURNAL OF CLINICAL ONCOLOGY, 35(8).
Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2019). Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply. JOURNAL OF CLINICAL ONCOLOGY, 37(9), 755-+.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., … Zinzan, P. L. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. LANCET, 393(10168), 229–40.
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., … Sharman, J. (2019). Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). LANCET HAEMATOLOGY, 6(5), E254–E265.
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study Park, S. I., Horwitz, S. M., Foss, F. M., Pinter-Brown, L. C., Carson, K. R., Rosen, S. T., … Shustov, A. R. (2019). The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. CANCER, 125(9), 1507–17.
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma Evens, A. M., Advani, R. H., Helenowski, I. B., Fanale, M., Smith, S. M., Jovanovic, B. D., … Hamlin, P. A. (2018). Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(30), 3015-+.
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(28), 2845-+.
Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation Aghighi, M., Theruvath, A. J., Pareek, A., Pisani, L. L., Alford, R., Muehe, A. M., … Daldrup-Link, H. E. (2018). Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. CLINICAL CANCER RESEARCH, 24(17), 4110–18.
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R., Connors, J. M., … Straus, D. J. (2019). Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. CLINICAL CANCER RESEARCH, 25(6), 1718–26.
Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy Moding, E. J., Advani, R., Rosenberg, S. A., & Hoppe, R. T. (2018). Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. RADIOTHERAPY AND ONCOLOGY, 129(3), 507–12.
Risk-adapted therapy for advanced-stage Hodgkin lymphoma Spinner, M. A., & Advani, R. H. (2018). Risk-adapted therapy for advanced-stage Hodgkin lymphoma. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 200–206.
Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma Spinner, M. A., Varma, G., & Advani, R. H. (2019). Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 184(1), 17–29.
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., … Smith, S. M. (2018). CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 379(18), 1711–21.
Novel Approaches in Waldenstrom Macroglobulinemia Spinner, M. A., Varma, G., & Advani, R. H. (2018). Novel Approaches in Waldenstrom Macroglobulinemia. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 32(5), 875-+.
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., … Flinn, I. W. (2019). Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget, 10(38), 3827–30.
Noninvasive molecular subtyping and risk stratification of DLBCL. Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Noninvasive molecular subtyping and risk stratification of DLBCL. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., … Sundar, H. (2019). B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(6), 651–61.
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Lansigan, F., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., … Foss, F. M. (2019). Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematologica, 1–11.
A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. Sawas, A., Savage, K. J., Perez, R. P., Advani, R. H., Melhem-Bertrandt, A., Lackey, J., … O'Connor, O. A. (2016). A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era. Keegan, T. H. M., Clarke, C. A., Rosenberg, A. S., Advani, R. H., Jonas, B. A., Flowers, C., & Tao, L. (2016). Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features Menke, J., Spinner, M., Shrestha, B., Advani, R., Natkunam, Y., & Gratzinger, D. (2019). CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features. LABORATORY INVESTIGATION, 99.
CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features Menke, J., Spinner, M., Shrestha, B., Advani, R., Natkunam, Y., & Gratzinger, D. (2019). CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features. MODERN PATHOLOGY, 32.
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Rosenwald, A., Bens, S., Advani, R., Barrans, S., Copie-Bergman, C., Elsensohn, M.-H., … Maucort-Boulch, D. (2019). Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1900743.
Response to A+CHP by CD30 expression in the ECHELON-2 trial. Advani, R. H., Horwitz, S. M., Iyer, S. P., Bartlett, N. L., Kim, W. S., Tilly, H., … Illidge, T. (2019). Response to A+CHP by CD30 expression in the ECHELON-2 trial. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. Jagadeesh, D., Horwitz, S. M., Bartlett, N. L., Advani, R. H., Jacobsen, E. D., Duvic, M., … Kim, Y. H. (2019). Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408. Thanarajasingam, G., Dueck, A. C., Novotny, P. J., Habermann, T. M., Advani, R. H., Gascoyne, R. D., … Hong, F. (2019). Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia Castillo, J., Allan, J., Siddiqi, T., Advani, R., Keezer, A., Gustine, J., … Treon, S. (2019). Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(10), E39–E40.
Incidence and Outcomes of Rare T cell Lymphomas from the T Cell Project: Hepatosplenic, Enteropathy Associated and Peripheral Gamma Delta T cell Lymphomas. Foss, F. M., Horwitz, S. M., Civallero, M., Bellei, M., Marcheselli, L., Kim, W. S., … Federico, M. (2019). Incidence and Outcomes of Rare T cell Lymphomas from the T Cell Project: Hepatosplenic, Enteropathy Associated and Peripheral Gamma Delta T cell Lymphomas. American Journal of Hematology.
Updates in Treatment Strategies for Hodgkin Lymphoma Advani, R. H. (2019). Updates in Treatment Strategies for Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(11), 1411–13.
A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY Fowler, N., Sharman, J., Smith, S., Pollyea, D., Boyd, T., Grant, B., … Advani, R. (2010). A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY. HAEMATOLOGICA, 95, 371.
PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., … Humerickhouse, R. (2010). PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES. HAEMATOLOGICA, 95, 371.
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Torka, P., Kothari, S. K., Sundaram, S., Li, S., Medeiros, L. J., Ayers, E. C., … Hernandez-Ilizaliturri, F. J. (2020). Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances, 4(2), 253–62.
Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Straus, D. J., Dlugosz-Danecka, M., Alekseev, S., Illes, A., Picardi, M., Lech-Maranda, E., … Gallamini, A. (2020). Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood.
Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Horst, K. C., Hancock, S. L., Ognibene, G., Chen, C., Advani, R. H., Rosenberg, S. A., … Hoppe, R. T. (2014). Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 25(4), 848–51.
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J., … Advani, R. (2020). Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. British Journal of Haematology.
POPULATION PHARMACOKINETICS OF MAGROLIMAB (5F9, HU5F9--G4) IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS. Agoram, B., Jin, C., Wang, B., Sikic, B., Advani, R., Chao, M., & Takimoto, C. (2020). POPULATION PHARMACOKINETICS OF MAGROLIMAB (5F9, HU5F9--G4) IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS. CLINICAL PHARMACOLOGY & THERAPEUTICS, 107, S85.
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Fowler, N. H., Nastoupil, L., De Vos, S., Knapp, M., Flinn, I. W., Chen, R., … Palomba, M. L. (2020). The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. British Journal of Haematology.
Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG. Binkley, M. S., Rauf, M. S., Milgrom, S. A., Pinnix, C. C., Tsang, R. W., Dickinson, M., … Hoppe, R. T. (2020). Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG. Blood.
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Merryman, R. W., Carreau, N. A., Advani, R. H., Spinner, M. A., Herrera, A. F., Chen, R., … Armand, P. (2020). Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. The Oncologist.
Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. Lynch, R. C., Sundaram, V., Desai, M., Henry, S., Wood, D., Daadi, S., … Advani, R. (2020). Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. JCO Oncology Practice, JOP1900733.
Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON-2 trial Illidge, T., Horwitz, S., Iyer, S., Bartlett, N., Kim, W. S., Belada, D., … Advani, R. (2020). Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON-2 trial. BRITISH JOURNAL OF HAEMATOLOGY, 189, 111–12.
Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study Radford, J., Bartlett, N., Straus, D., Dlugosz-Danecka, M., Alekseev, S., Illes, A., … Picardi, M. (2020). Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study. BRITISH JOURNAL OF HAEMATOLOGY, 189, 101–2.
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Carreau, N. A., Armand, P., Merryman, R. W., Advani, R. H., Spinner, M. A., Herrera, A. F., … Diefenbach, C. (2020). Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. British Journal of Haematology.
Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation. Weil, C. R., Qian, Y., Von Eyben, R., Daadi, S. E., Corbelli, K. S., Rosenberg, S. A., … Hoppe, R. T. (2020). Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation. Leukemia & Lymphoma, 1–7.
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Armand, P., Bello, C. M., … Ogba, N. (2020). Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(6), 755–81.
A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Evens, A. M., Hong, F., Habermann, T. M., Advani, R. H., Gascoyne, R. D., Witzig, T. E., … Kahl, B. (2020). A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9).
An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma Steen, C. B., Luca, B. A., Esfahani, M. S., Nabet, B. Y., Sworder, B., Farshidfar, F., … Alizadeh, A. A. (2019). An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. BLOOD, 134.
Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies Garofalo, A., Schroers-Martin, J. G., Soo, J., Kurtz, D. M., Sworder, B., Liu, C. L., … Alizadeh, A. A. (2019). Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. BLOOD, 134.
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Carreau, N. A., Pail, O., Armand, P., Merryman, R., Advani, R. H., Spinner, … Diefenbach, C. (2020). Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. The Oncologist.
Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade. Diefenbach, C. S. M., Hong, F., Ambinder, R. F., Cohen, J. B., David, K. A., Advani, R. H., … Ansell, S. M. (2018). Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade. JOURNAL OF CLINICAL ONCOLOGY, 36(15).
Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results. Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R. W., Feldman, T., … Connors, J. M. (2018). Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results. JOURNAL OF CLINICAL ONCOLOGY, 36(15).
Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study. Evens, A. M., Advani, R. H., Fanale, M. A., Smith, S. M., Helenowski, I. B., Bociek, G., … Hamlin, P. A. (2018). Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study. JOURNAL OF CLINICAL ONCOLOGY, 36(15).
Consensus Statement on the Management of Waldenstrom Macroglobulinemia Patients During the COVID-19 Pandemic. Talaulikar, D., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., … Castillo, J. J. (2020). Consensus Statement on the Management of Waldenstrom Macroglobulinemia Patients During the COVID-19 Pandemic. HemaSphere, 4(4), e433.
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Diefenbach, C. S., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., David, K. A., … Ansell, S. M. (2020). Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. The Lancet. Haematology, 7(9), e660–e670.
Angioimmunoblastic T-Cell Lymphoma: Report on 282 Cases from the Prospective International T-Cell Lymphoma Project Skrypets, T., Civallero, M., Manni, M., Pileri, S., Weisenburger, D. D., Ko, Y. H., … Advani, R. H. (2020). Angioimmunoblastic T-Cell Lymphoma: Report on 282 Cases from the Prospective International T-Cell Lymphoma Project. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 20, S253–S254.
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. Treon, S. P., Meid, K., Gustine, J., Yang, G., Xu, L., Liu, X., … Castillo, J. J. (2020). Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2000555.
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial Diefenbach, C. S., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., David, K. A., … Ansell, S. M. (2020). Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. LANCET HAEMATOLOGY, 7(9), E660–E670.
Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. Allen, P. B., Savas, H., Evens, A. M., Advani, R., Palmer, B., Pro, B., … Winter, J. N. (2020). Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. Blood.
CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. Menke, J. R., Spinner, M. A., Natkunam, Y., Warnke, R. A., Advani, R. H., & Gratzinger, D. A. (2020). CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. Archives of Pathology & Laboratory Medicine.
The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs) Truemper, L., O'Connor, O. A., Pro, B., Illidge, T. M., Advani, R. H., Bartlett, N. L., … Horwitz, S. M. (2019). The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs). ONCOLOGY RESEARCH AND TREATMENT, 42, 23.
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Ghione, P., Faruque, P., Mehta-Shah, N., Seshan, V., Ozkaya, N., Bhaskar, S., … Horwitz, S. (2020). T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Advances, 4(19), 4640–47.
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Cheson, B. D., Bartlett, N. L., LaPlant, B., Lee, H. J., Advani, R. J., Christian, B., … Ansell, S. M. (2020). Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. The Lancet. Haematology.
Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) RU051505I. Cheson, B. D., Bartlett, N. L., LaPlant, B., Lee, H. J., Advani, R. H., Christian, B., … Ansell, S. M. (2020). Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) RU051505I. JOURNAL OF CLINICAL ONCOLOGY, 38(15).
Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium. Fu, K., Yu, G., Bi, C., Cheng, H., Smith, L., Yuan, J., … Vose, J. (2020). Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium. JOURNAL OF CLINICAL ONCOLOGY, 38(15).
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Castillo, J. J., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., … Kastritis, E. (2020). Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. The Lancet. Haematology, 7(11), e827–e837.
Partial response or better at sixmonths is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib. Castillo, J. J., Abeykoon, J. P., Gustine, J. N., Zanwar, S., Mein, K., Flynn, C. A., … Treon, S. P. (2020). Partial response or better at sixmonths is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology.
Long-Term Outcomes For Stage I-II Diffuse Large B-Cell Lymphoma Treated With Rituximab And Chemotherapy With Or Without Radiotherapy Binkley, M. S., Hiniker, S. M., Younes, S., Yoo, C., Wignarajah, K., Jin, M., … Hoppe, R. T. (2020). Long-Term Outcomes For Stage I-II Diffuse Large B-Cell Lymphoma Treated With Rituximab And Chemotherapy With Or Without Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 108(3), E758.
Outcomes Of Adult Patients With Lymphoma Treated With Nonmyeloablative Total Lymphoid Irradiation For Stem Cell Transplant (SCT) Conditioning With A Boost To High Risk Or Gross Disease Dworkin, M. L., Hiniker, S. M., Von Eyben, R., Spinner, M. A., Advani, R. H., Lowsky, R., & Hoppe, R. T. (2020). Outcomes Of Adult Patients With Lymphoma Treated With Nonmyeloablative Total Lymphoid Irradiation For Stem Cell Transplant (SCT) Conditioning With A Boost To High Risk Or Gross Disease. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 108(3), E752–E753.
Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia Castillo, J. J., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., … Kastritis, E. (2020). Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia. LANCET HAEMATOLOGY, 7(11), E827–E837.
Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study Moskowitz, A. J., Advani, R. H., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., … Herrera, A. F. (2019). Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. BLOOD, 134.
Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study Witzig, T. E., Sokol, L., Foss, F. M., Kim, W.-S., Jacobsen, E., De La Cruz, M. de F., … Gualberto, A. (2019). Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. BLOOD, 134.
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A plus CHP) in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant Savage, K. J., Horwitz, S. M., Advani, R. H., Christensen, J. H., Domingo-Domenech, E., Rossi, G., … Iyer, S. P. (2019). An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A plus CHP) in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant. BLOOD, 134.
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) Bannerji, R., Allan, J. N., Arnason, J. E., Brown, J. R., Advani, R. H., Barnes, J. A., … Topp, M. S. (2019). Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). BLOOD, 134.
Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Ballas, L. K., Metzger, M. L., Milgrom, S. A., Advani, R., Bakst, R. L., Dabaja, B. S., … Constine, L. S. (2020). Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Leukemia & Lymphoma, 1–14.
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents Sica, R. A., Spinner, M. A., Tamaresis, J. S., Advani, R. H., Johnston, L. J., Lowsky, R., … Arai, S. (2019). Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. BLOOD, 134.
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma Kumar, A., Casulo, C., Advani, R. H., Budde, L. E., Barr, P. M., Batlevi, C. L., … Moskowitz, C. H. (2019). A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. BLOOD, 134.
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma Hamid, M. S., Rutherford, S. C., Kim, S., Bartlett, N. L., Malecek, M.-K., Watkins, M., … Ramchandren, R. (2019). North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. BLOOD, 134.
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study Bartlett, N. L., Straus, D. J., Dlugosz-Danecka, M., Alekseev, S., Illes, A., Lech-Maranda, E., … Picardi, M. (2019). Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. BLOOD, 134.
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma Merryman, R. W., Redd, R. A., Nieto, Y., Rao, U., Byrne, M. T., Bond, D. A., … Herrera, A. F. (2019). Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. BLOOD, 134.
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis Orellana-Noia, V. M., Isaac, K., Wages, N. A., Malecek, M.-K., Bartlett, N. L., Voorhees, T. J., … Portell, C. A. (2019). Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. BLOOD, 134.
Long-Term Outcomes of Patients with Early-Stage Non-Bulky Hodgkin Lymphoma Treated with Combined Modality Therapy on the Stanford V Trials (The G4 and G5 Studies). Mou, E., Advani, R. H., von Eyben, R., Rosenberg, S. A., & Hoppe, R. T. (2020). Long-Term Outcomes of Patients with Early-Stage Non-Bulky Hodgkin Lymphoma Treated with Combined Modality Therapy on the Stanford V Trials (The G4 and G5 Studies). International Journal of Radiation Oncology, Biology, Physics.

View All 558 Publications

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Cancer, Any Cancer or Solid Tumor, Lymphoma

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Cancer, Lymphoma,

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Cancer, Lymphoma,

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma Cancer, Lymphoma,

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type Cancer, Lymphoma,

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Cancer, Lymphoma,

The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

4.9

Friendliness

4.9

Friendliness

4.9

Explanations

4.9

Explanations

4.8

Listens

4.8

Listens

4.8

Care provider's efforts to include you in decisions about your care

4.8

Care provider's efforts to include you in decisions about your care

4.9

Clear Communication

4.9

Clear Communication

4.9

Confidence in your doctor

4.9

Confidence in your doctor

4.9

Recommended to others

4.9

Recommended to others

3.9

Wait times

3.9

Wait times

SHC Patient, Oct 2020

I am totally full of gratitude and my heart is full of love for all the ladies and gentleman involved in my care. I am amazed of the care given to me from my arrival to saying goodbye!

SHC Patient, Sep 2020

Dr. Advani is caring, patient, knowledgeable and answered all my concerns.

SHC Patient, Aug 2020

I always have a very good experience. I have and always will recommend Dr. Advani and may to anyone needing cancer care.

SHC Patient, Jul 2020

Dr. Advani and I have been doctor/patient for a long time. She is very "tuned in" to my fears & concerns and always received them with kindness and sensitivity. I'm so lucky to have her!

SHC Patient, Apr 2020

I considered it a privilege to meet with Dr. Advani. Due to COVID-19, she was here.

SHC Patient, Mar 2020

No words to say 'thank you' to Dr. Advani. She saved my life and has checked on me.

SHC Patient, Mar 2020

Dr. Advani went above & beyond to speak to me both a physician & patient. She spent an incredible amount of time with me and made me feel at ease. She is incredibly knowledgeable about her field and I am so lucky to call her my oncologist. She is excellent, kind and caring!

SHC Patient, Feb 2020

Dr. Advani is a wonderful doctor! She cares about her patients.

SHC Patient, Jan 2020

Dr. Advani is terrific.

SHC Patient, Jan 2020

He was a fellow and working under Dr. Advani.

SHC Patient, Dec 2019

I work in biotechnology field and KNOW doctors. Dr. Advani is one of the best I've ever had the pleasure of knowing. You are very lucky to have her on your staff.

SHC Patient, Dec 2019

If there were higher marks available to give to Advani & her team, I would give them to her.

Patient Comments

Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

SHC Patient, Oct 2020

I am totally full of gratitude and my heart is full of love for all the ladies and gentleman involved in my care. I am amazed of the care given to me from my arrival to saying goodbye!

SHC Patient, Sep 2020

Dr. Advani is caring, patient, knowledgeable and answered all my concerns.

SHC Patient, Aug 2020

I always have a very good experience. I have and always will recommend Dr. Advani and may to anyone needing cancer care.

SHC Patient, Jul 2020

Dr. Advani and I have been doctor/patient for a long time. She is very "tuned in" to my fears & concerns and always received them with kindness and sensitivity. I'm so lucky to have her!

SHC Patient, Apr 2020

I considered it a privilege to meet with Dr. Advani. Due to COVID-19, she was here.

SHC Patient, Mar 2020

No words to say 'thank you' to Dr. Advani. She saved my life and has checked on me.

SHC Patient, Mar 2020

SHC Patient, Feb 2020

Dr. Advani is a wonderful doctor! She cares about her patients.

SHC Patient, Jan 2020

Dr. Advani is terrific.

SHC Patient, Jan 2020

He was a fellow and working under Dr. Advani.

SHC Patient, Dec 2019

I work in biotechnology field and KNOW doctors. Dr. Advani is one of the best I've ever had the pleasure of knowing. You are very lucky to have her on your staff.

SHC Patient, Dec 2019

If there were higher marks available to give to Advani & her team, I would give them to her.

SHC Patient, Dec 2019

Dr. Ranjana is excellent.

SHC Patient, Dec 2019

When describing the chemotherapy, we couldn't follow well w/the names. Perhaps our fault for not asking for notes after the visit.

SHC Patient, Nov 2019

Good.

SHC Patient, Nov 2019

Dr. Advani is excellent.

SHC Patient, Oct 2019

It is always a pleasure to see Dr. Advani (despite the circumstances). We also met Dr. Karimi this time and we were very impressed.

SHC Patient, Oct 2019

Dr. Advani is an excellent diagnostician and caring provider.

SHC Patient, Jul 2019

Excellent!!

SHC Patient, Jun 2019

Dr. Advani is singularly one of the hardest working, compassionate and intelligent physicians I have ever had take care of me. And May Cao is wonderful to see, also.

SHC Patient, Apr 2019

Words could not express my thanks to Dr. Advani for her incredible medical care & personal concern. The very best!

SHC Patient, Mar 2019

Dr. Advani (and her assistant) were clear, attentive and warm in addition to being professional.

SHC Patient, Feb 2019

Dr. Advani is excellent!

SHC Patient, Nov 2018

The doctors could have spent more time with me in comparison with the amount of time I spent waiting.

SHC Patient, Nov 2018

Excellent doctor.

SHC Patient, Oct 2018

Dr. Advani is a very kind, very knowledgeable and supportive member of my care team - She works well with my local oncologist - Great communication all around.

SHC Patient, Sep 2018

Dr. Advani is an excellent oncologist. She is caring, informative, on time & I believe she is superior in her care of her patients.

SHC Patient, Jul 2018

I have seen Dr. Advani for 17 years. I continue to see her because of her exceptional knowledge, judgment & compassion.

SHC Patient, Jun 2018

Dr. Advani and Dr. Shomali were both very professional. Great "bedside manner," compassionate and respectful.

SHC Patient, Jun 2018

Very good.

SHC Patient, May 2018

Very good.

SHC Patient, Mar 2018

Absolutely no complaints, complete confidence in this care provider.

SHC Patient, Jan 2018

Dr. Advani is amazing, she makes you feel like you're her only patient.

SHC Patient, Nov 2017

Very good.

SHC Patient, Nov 2017

It's beyond this survey. I left that day feeling like Dr. Advani & team can save my life. I cannot put that into words.

SHC Patient, Oct 2017

My wife and I were extremely pleased w/our visit with Dr. Advani and Dr. Skinner. They built immediate rapport and trust as they thoughtfully explained my condition.

SHC Patient, Jul 2017

Delighted with Dr. Advanti!

SHC Patient, Jun 2017

Was very informative and honest, straight forward. Laid treatment diagnosis and their plan all out no hidden pieces/parts. Really liked it.

SHC Patient, May 2017

Good.

SHC Patient, May 2017

Dr. Advani is incredible.

SHC Patient, May 2017

Dr. Advani is the ultimate physician: Great knowledge, great judgment, great care. Her staff professionals are excellent. I live today in great part because of her care -

SHC Patient, May 2017

I have only good things to describe. everyone was very helpful, caring, and really lovely.

SHC Patient, May 2017

Dr. Advani is excellent in keeping us aware of my condition & what I should expect going forward.

SHC Patient, Mar 2017

Both doctor and PA were exceptional in their care. I'm very fortunate to have be accepted by Dr. Advani for my care.

SHC Patient, Mar 2017

My providers see several patients. They don't waste time, but they don't rush me. I always get clear answers. They take the time that is necessary to answer my questions.

SHC Patient, Feb 2017

Keep up the excellent work.

SHC Patient, Feb 2017

I am grateful.

SHC Patient, Jan 2017

I couldn't be more pleased with the superb care.

SHC Patient, Nov 2016

Dr. Advani did a great job of explaining things and answering questions.

SHC Patient, Oct 2016

All good.

SHC Patient, Oct 2016

Dr. Advani & her nurse Kelly have been amazing at getting back to me via email & have done a great job answering my questions during this stressful time.

SHC Patient, Sep 2016

Dr. Advani is a brilliant physician/researcher in the field of lymphoma. It is a privilege to be seen by her.

SHC Patient, Aug 2016

Very good attention.

SHC Patient, Aug 2016

Dr. Advani and her staff - I find them to be exceptional!

SHC Patient, May 2016

Dr Advoni is amazing!

SHC Patient, Mar 2016

Concern showed by Dr. Advani helped deal with questions. Very helpful.

SHC Patient, Feb 2016

It is my opinion that Dr. Advani is the finest Oncologist and Scientist in the disciplne of Lymphoma Oncology, in the world. As a level 4 patient, since 2011, I am alive, feel wonderful... as we attack the Lymphoma as it pops up. Dr. Advani knows her patients well, is honest, and makes us part of her protocol for healing. I trust her with all of my heart.......She is truly the best. I must also add her love and appreciation for my family is endearing......adding, likewise her team.....Katie Pose has been part of my program from the beginning of my Lymphoma ( Mantle Cell) treatments.....She is like a member of my "get well and healing" family!

SHC Patient, Feb 2016

We recommend Stanford, our doctor and or nurse practitioner frequently.

SHC Patient, Feb 2016

Dr. Advanti is wonderful. She is very personable and very efficient and right to the point. We love her.

SHC Patient, Dec 2015

I appreciate Dr. Advani's warmth and caring nature. I trust her knowledge and concerns in treating my lymphoma. She makes me part of the team! I feel encouraged and helpful and move through my treatment. She is wonderful and surrounds herself with a positive support team. I am so pleased she is my oncologist - She is the best!

SHC Patient, Dec 2015

My care provider full of humility & heavenly touch in her hands.

SHC Patient, Dec 2015

Very busy operation!

SHC Patient, Nov 2015

I always feel I get as much time as I need.

SHC Patient, Nov 2015

Excellent in all regards.

SHC Patient, Nov 2015

Dr. Advani is well worth the trip to California to see.

SHC Patient, Aug 2015

Care provider was very knowledgeable regarding my condition.

SHC Patient, Aug 2015

I recommend everyone w/lymphoma to go to Advani.

SHC Patient, Jul 2015

Excellent.

SHC Patient, Jul 2015

The best!

SHC Patient, Jun 2015

Dr Advani is always exceptional and I count myself lucky to be in her care.

SHC Patient, Jun 2015

I hope no one needs this type of care provider.

SHC Patient, Jun 2015

Excellent care, knowledge, personality.

SHC Patient, Mar 2015

Keep-up the good work.

SHC Patient, Feb 2015

Never bad experience.

SHC Patient, Jan 2015

dr. Advani is an outstanding doctor & human being. She shows great compassion.

SHC Patient, Nov 2014

Very thorough & caring!

SHC Patient, Nov 2014

The medical team was very thorough and detailed about my health history.

SHC Patient, Nov 2014

So thankful for their help!

SHC Patient, Nov 2014

We have a great deal of confidence in Dr. Advani for care of our "orphan" cancer.

SHC Patient, Oct 2014

As I mentioned above, I feel very fortunate to have Dr. Advani and her team taking care of me. I have received outstanding care.

SHC Patient, Oct 2014

Nicest, most respectful, most informative high level expert I have ever talked with and I have met many.

SHC Patient, Oct 2014

I very thankful to have Dr. Advani as my doctor. She is the best.

SHC Patient, Jul 2014

No problem with provider. Big problem with Stanford access & coordination & communication.

SHC Patient, Jul 2014

Dr. Advani is amazing, she listens & acts. I am here because of her wise actions.

SHC Patient, Jun 2014

Dr. took the time to have us admitted because of the urgency needed w/medical care.

SHC Patient, Jun 2014

Dr. Advani is and has been an excellent oncologist for me. Bar none - the best!

SHC Patient, Jun 2014

Dr. Advani saved my life!

SHC Patient, Jun 2014

Very experienced - Highly professional salute her patience - Every time I visit her, it is the best one.

SHC Patient, May 2014

Dr. Advani is an outstanding oncologist as are the members of her team.

SHC Patient, May 2014

Dr. & her assistant represent the best in health care.

SHC Patient, May 2014

I feel so fortunate and thankful to have Dr. Advani.

SHC Patient, Apr 2014

Dr. Advani is excellent! She saved my life. Drs. and nurse practitioners are overworked.

SHC Patient, Mar 2014

Dr. Advani has been wonderful.

SHC Patient, Mar 2014

Dr. Advani dismissed my concerns completely, made me feel like I was a nuisance/hypochondriac. Dr. Advani has NO bedside manner.

SHC Patient, Feb 2014

I'm in total remission for 2 years Dr. Advani & I exchanged info about my remarkable recovery.

SHC Patient, Feb 2014

Dr. showed caring for the pt.

SHC Patient, Dec 2013

Everyone was FANTASTIC and we always had a great time!

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Ranjana Advani

Ranjana Advani

Medical oncologist, Lymphoma specialist

Lymphoma Program

Cancer Immunotherapy Program

Practice Areas

Professional Education

Administrative Appointments

Publications

Patient Comments